



1 30 June 2022
2 EMA/CVMP/499555/2021
3 Committee for Veterinary Medicinal Products

4 **Draft report on the development of a harmonised**
5 **approach to exposure assessment methodologies for**
6 **residues from veterinary medicinal products, feed**
7 **additives and pesticides in food of animal origin**
8 Draft report from the Working Group

Draft agreed by the Working Group	March 2022
Adopted by CVMP for release for consultation	13 April 2022
Endorsed by EFSA Scientific Committee for release for consultation	28 April 2022
Reviewed by European Commission	1 June 2022
Start of public consultation	30 June 2022
End of consultation (deadline for comments)	31 August 2022

9 Comments should be provided using this [template](#). The completed comments form should be sent to
10 Vet-Guidelines@ema.europa.eu

Keywords	Consumer exposure, dietary, residues, veterinary medicinal products, feed additives, pesticides
----------	---

11



12	Table of contents	
13	1. Introduction and problem statement.....	4
14	2. Terms of reference as provided to EFSA and EMA	5
15	3. Background information on concepts, data and models.....	5
16	3.1. Hazard assessment	6
17	3.2. Considerations regarding exposure and risk characterisation	6
18	3.3. Studies used and requirements to derive residue (occurrence) data.....	7
19	3.4. Exposure models used	10
20	3.4.1. Veterinary medicinal Products	10
21	3.4.2. Feed Additives	11
22	3.4.3. Pesticides.....	12
23	3.4.4. Summary of approaches EMA, EFSA, JECFA, JMPR.....	15
24	4. Exercise to compare the estimates of dietary exposure from different	
25	models.....	20
26	4.1. Model data sets	20
27	4.2. Chronic Exposure	25
28	4.2.1. Bovine meat and offal and milk	26
29	4.2.2. Chicken (poultry) meat and offal and eggs	30
30	4.2.3. Fish	32
31	4.2.4. Honey.....	33
32	4.2.5. Combined exposure for a substance used in all food producing species.....	34
33	4.3. Acute Exposure.....	35
34	4.3.1. Bovine (mammals) meat and offal and milk.....	36
35	4.3.2. Chicken (poultry) meat and offal and eggs	38
36	4.3.3. Fish	41
37	4.3.4. Honey.....	42
38	5. Exercise to compare consumption figures of different models, using a	
39	default residue value of 1 mg/kg	43
40	5.1. Chronic exposure	44
41	5.2. Acute exposure.....	48
42	6. Comparison and evaluation of the exposure models.....	52
43	6.1. Discussion of chronic exposure models	52
44	6.1.1. Some general remarks on concepts, assumptions and data used	52
45	6.1.2. Specific remarks on models using food consumption survey data (FACE, PRIMo 4 and	
46	GECDE).....	54
47	6.1.3. Specific remarks on the model diet based approach (TMDI)	56
48	6.1.4. Specific remarks on the "balance sheet" based model (IEDI)	57
49	6.1.5. Specific remarks on collection and selection of occurrence values for residues	58
50	6.1.6. Specific remarks on chronic exposure from "multiple uses"	59
51	6.2. Discussion of models and calculation of acute exposure	59
52	6.2.1. Note regarding use of a TMDI approach in acute exposure assessments	60
53	6.3. Note regarding "less-than-life-time" approach	61
54	6.4. Note regarding possibilities to use JECFA and JMPR models	61

55	7. Summary and recommendations	62
56	7.1. Lessons learned	62
57	7.2. Recommendations for exposure estimation	63
58	7.2.1. Proposal for harmonisation in consumption data used	63
59	7.2.2. Proposal for harmonised residue (occurrence) input assumptions for acute and chronic	
60	exposure	64
61	7.2.3. Proposal for harmonised exposure model	67
62	7.2.4. Proposal for combining "chronic" exposure to residues from multiple uses in animal	
63	tissues	67
64	7.2.5. Proposal for harmonisation of some of technical aspects of the exposure approaches	
65	68
66	7.2.6. Thoughts on a harmonised use of exposure estimates in risk characterisation	
67	approaches.....	69
68	8. Conclusions and Outlook	70
69	9. References (scientific and/or legal)	73
70	10. Abbreviations	75
71		

72 **1. Introduction and problem statement**

73 A number of active substances can be used for different purposes, such as veterinary medicinal
74 products (VMP), feed additives, pesticides and biocides. Those substances are regulated under different
75 sectoral legislation and are assessed separately by European Medicines Agency (EMA) and/or European
76 Food Safety Authority (EFSA) and/or European Chemicals Agency (ECHA) in the context of this sectoral
77 legislation. Currently, different risk assessment methodologies are used with the potential for different
78 outcomes when conducting risk assessments on the same active substance. While it is acknowledged
79 that there are a number of factors that may lead to different risk assessment outcomes (e.g. different
80 data requirements in view of the different purposes of the studies, different assumptions and
81 approaches to hazard assessment, etc.), some of the different outcomes could be avoided by aligned
82 procedures, especially with regard to the exposure assessment procedures used (input data and
83 models) which often are the critical starting point in the risk assessment.

84 For veterinary medicinal products, EMA uses the Theoretical Maximum Daily Intake (TMDI) model to
85 estimate the risk from life-long consumer exposure to residues from animals treated with veterinary
86 medicinal products. This model was formerly also used by EFSA (EFSA's Panel on Additives and
87 Products or Substances used in Animal Feed - FEEDAP Panel) and by JECFA, but both EFSA and JECFA
88 have now moved away from the TMDI model, in favour of alternative models in accordance with the
89 development of scientific and computational tools in this field.

90 EFSA developed models for the assessment of consumer exposure of feed additives and pesticide
91 residues (FACE/PRIMo 4) allowing for age-dependent exposure scenarios based on individual food
92 consumption data whereas JECFA developed the Global Estimated Chronic Dietary Exposure (GECDE)
93 model.

94 Similarly, for substances with dual uses as VMPs and pesticides, maximum residue limits/levels (MRLs)
95 may be different for the same substance in the same animal commodity (muscle, fat, liver, kidney,
96 eggs or milk) or may have different residue definitions depending on different assumptions used and
97 different legislative frameworks under which the MRLs were established. This has led to uncertainties
98 for EU enforcement authorities as to the appropriate enforcement level and residue definition as a
99 basis to take enforcement action.

100 In view of these potential difficulties resulting from use of different exposure calculation models, the
101 European Commission mandated EFSA and EMA (in 2020) to provide scientific and technical assistance
102 in order to develop a common approach on exposure assessment methodologies for residues from
103 veterinary medicinal products, feed additives and pesticides residues in food of animal origin.

104 If other elements of possible harmonisation of risk assessment methodologies that could be pursued to
105 achieve their better alignment across the concerned sectors are identified, this should also be
106 highlighted in the Technical Report for further follow up by the Commission.

107 As Codex maximum residue limits are systematically considered in EU food legislation, the ongoing
108 developments at international level should also be considered in this mandate, namely the outcome of
109 the work carried out by the 2018 WHO/FAO joint working group of experts that dealt with
110 harmonisation issues for dual use substances. The outcome of this working group was a partial
111 alignment of exposure assessment methodology, which is now reflected in the revised Chapter 6 of the
112 draft EHC guidelines¹ and was welcomed by the EU as a step forward.

¹ FAO/WHO. Chapter 6 dietary exposure assessment of chemicals in food. In FAO/WHO. Principles and methods for the risk assessment of chemicals in food. Geneva: WHO; 2009

113 **2. Terms of reference as provided to EFSA and EMA**

114 The European Commission requested EFSA and EMA, to develop a common approach on exposure
115 assessment methodologies for residues from veterinary medicinal products, feed additives and
116 pesticides in a stepwise approach as detailed below:

117 1. By 31.12.2021,

118 a. Assess currently available exposure assessment models routinely used in the EU and on an
119 international level in Codex Alimentarius for veterinary medicinal products (VMPs), feed additives and
120 pesticides residues for their suitability for use in routine risk assessment in these areas and describe
121 their advantages and limitations overall and per area. Discuss whether alignment of existing models
122 would be possible and under which circumstances. Exemplary calculations on the same data sets (e.g.
123 for ongoing real assessments) should be considered to assess impacts of a change of methodology.

124 b. Assess in how far the jointly developed approach by JECFA and JMPR – once adopted - laid down in
125 Chapter 6 of the EHC risk assessment guidelines could be integrated, and under what circumstances.
126 Describe advantages and limitations.

127 2. By 30.11.2022,

128 a. Recommend a common approach for exposure assessment compatible with current scientific
129 knowledge for future use by EMA and EFSA in their routine assessments of VMPs, feed additives and
130 pesticides residues. The compatibility of the approach with internationally used approaches in these
131 areas should also be ensured.

132 **3. Background information on concepts, data and models**

133 In the regulatory framework for the establishment of residue limits related to veterinary medicinal
134 products (Regulation (EC) No 470/2009) and for feed additives (Regulation (EC) No 1831/2003), the
135 Maximum Residue Limit (MRL) is defined as the concentration of a residue from a pharmacologically
136 active substance which may be permitted in a particular foodstuff of animal origin. In the area of
137 pesticide residues (Regulation (EC) No 396/2005), the MRL stands for "Maximum Residue Level" which
138 is defined as the upper legal level of a concentration for a pesticide residue in or on food or feed set in
139 accordance with this Regulation, based on good agricultural practice (GAP) and the lowest consumer
140 exposure necessary to protect vulnerable consumers.

141 The MRLs are established such that substances in products used under authorised conditions do not
142 pose an unacceptable risk to consumers. The consumer risk assessment follows the same principles in
143 all regulatory sectors² and considers the metabolism and depletion of pharmacologically active
144 substances in relevant animal species, the type of residues and the amount thereof, that may be
145 ingested by human beings without an appreciable health risk. Points of reference in the risk
146 characterisation are typically based on a comprehensive hazard assessment and are expressed in
147 terms of an acceptable daily intake (ADI), acute reference dose (ARfD) or an alternative health based
148 guidance value (HBGV) (see Regulation (EC) No 470/2009, Regulation (EC) No 1831/2003 and
149 Regulation (EC) No 429/2008).

² E.g. as described in WHO/IPCS (World Health Organization/International Programme on Chemical Safety), 2009. Principles and Methods for the Risk Assessment of Chemicals in Food, International Programme on Chemical Safety, Environmental Health Criteria 240. Available online: <http://www.who.int/ipcs/food/principles/en/index1.html>

150 **3.1. Hazard assessment**

151 The hazard assessment follows comparable internationally established principles and study
152 requirements laid down in certain guidelines (e.g. EHC 240, OECD or also specific EU guidelines).

153 For the establishment of HBGVs for chronic exposure, similar approaches are used by EMA, EFSA, JMPR
154 and JECFA. In short, data on pharmacological and toxicological activity of the particular active
155 compound are assessed and dose-response relationships are modelled. In case of microbiologically
156 active compounds, data on microbiological properties are also taken into account. These data are used
157 to identify No Observed Adverse Effect Levels (NOAELs) or benchmark dose levels (BMDL) (or No
158 Observed Effect Concentrations (NOEC) for in vitro endpoints) and to establish a HBGV, typically an
159 ADI or a tolerable upper intake level (UL), depending on the nature of the substance under
160 assessment. To derive suitable HBGVs, NOAELs or BMDLs are adjusted by uncertainty factor(s)
161 (typically 100) to cover intra- and interspecies variation.

162 If necessary, EFSA, JMPR and JECFA establish ARfDs based on the same principles as described above
163 for ADIs. Only short-term effects are taken into account. Currently no ARfDs are derived by EMA, but
164 endpoints for certain ADIs are based on short-term effects (e.g. pharmacological effects).

165 **3.2. Considerations regarding exposure and risk characterisation**

166 The experimental studies required for exposure assessment of veterinary medicinal products,
167 pesticides and feed additives are defined in Commission Regulation (EU) 2018/782, Regulation (EC) No
168 1107/2009³ and Commission Regulation (EC) No 429/2008. The aim of the studies is to first evaluate
169 the nature and fate of the substance. This is most often accomplished in studies using radiolabelled
170 substances. Other specific studies may also be designed to quantify the residue concentrations in the
171 edible tissues/food commodities from target animals. Depending on the specific requirements, the
172 latter studies will investigate different dosing regimens/levels and/or depletion times.

173 The residue considered in the dietary exposure assessment is the relevant "residue of concern" (RoC)⁴.
174 When determining RoC⁵, the most common approach (e.g. when evaluating substances used in VMPs)
175 is to assume, by default, that all metabolites have the same pharmacological/toxicological potential as
176 the parent compound. In this case, the RoC would be the total residue (sum of residue components).
177 Yet, for the purpose of residue monitoring, it may not be feasible to measure concentrations for all
178 compounds considered in the RoC, and a marker residue⁶ may need to be defined.

179 The risk is characterised by a comparison of the estimate of dietary exposure to the RoC with the
180 appropriate HBGV (ADI in case of chronic risk and ARfD in case of acute risk). In the framework of a
181 pre-authorisation assessment (i.e. in view of authorising a VMP, feed additive or pesticide), robust
182 information on the frequency of use of a chemical and its actual occurrence in food may not (yet) be
183 available. Hence, for the dietary exposure assessment, it is assumed by default that all animals are
184 treated with or exposed to the chemical.

³ In particular, in the related Regulations on data requirements.

⁴ partly different terminology is used for this concept in the various fields (e.g. residue definition for risk assessment for pesticide residues).

⁵ = absence of concern that metabolites have a higher toxicity

⁶ The marker residue is the residue selected for residue monitoring and is in a known relationship to total residues in edible products

185 **3.3. Studies used and requirements to derive residue (occurrence) data**

186 This chapter is intended to give an overview of the residue studies and guidelines used in the different jurisdictions. The overview is given in table 1

187 **Table 1: Overview of residue studies used in the different fields and different organisations**

		Veterinary Medicinal Products			Feed Additives		Pesticides
		EMA		JECFA	EFSA		JMPR, EFSA
		MRL (VICH ⁷ GL46, GL56, GL57)	Withdrawal Period* (VICH GL48, GL56, GL57)	MRL	TR study**	MR***	Accumulating feeding studies (OECD TG 505 /a)
Meat and offal	Mammals	≥3 animals/time point	Minimum 4 animals/time point at a minimum of 4 time points 6 animals for 0- day WP (i.e. one time point study)	JECFA is mostly reusing data from regional product authorisations, e.g. EMA/FDA/JMAFF, other Ideally data acc. to VICH GL46, GL56, GL57, GL48, GL56, GL57 are available	≥3 dairy cows, sows ≥4 cattle, pigs, rabbits	≥4 dairy cows, cattle, pigs, sows, rabbits	Dairy cattle (rarely beef cattle, goat or swine) 3 animals per dose group, 3 dose groups, at least 28d dosing Sampling of tissues after last administration Depuration for up to +2 weeks optional
	Poultry	≥3 animals/time point	6 animals/time point minimum of 4 time points 12 animals for 0- day WP (i.e. one time point study)	For example studies as mentioned for EMA	≥ 3 laying hens ≥4 poultry and related minor species	≥6 poultry	Laying hens (rarely broiler chicken) 5 animals per dose group, 3 dose groups, at least 28d dosing Sampling of eggs (all days) Sampling of tissues after last administration Depuration for up to +2 weeks optional

⁷ VICH is a trilateral (EU/EMA-Japan-USA) programme aimed at harmonising technical requirements for veterinary product registration.

	Fish	10 animals/time point	10 animals/time point minimum of 4 time points 15 animals for 0-day WP (i.e. one time point study)		≥10 salmonids and other aquatic species	≥10 salmonids and other aquatic species	No agreed guideline yet, not considered in JMPR
Milk		≥8	least 20 animals for a sufficient time period		at least eight cows (24 h pooled milk)	at least eight cows (24 h pooled milk)	Same study as for meat and offal: Dairy cattle (rarely goat) 3 animals per dose group, 3 dose groups, at least 28d dosing Sampling of milk (all days)
Eggs		≥10 eggs/day for laying birds over a sufficiently long time period.	At least 10 eggs per time point		sufficient number of laying hens to collect 10 eggs	sufficient number of laying hens to collect 10 eggs	Same study as for meat and offal: Laying hens 5 animals per dose group, 3 dose groups, at least 28d dosing Sampling of eggs (all days)
Honey		6 colonies per site, 4 sites	6 colonies per site, 4 sites		six bee hives	six bee hives	No agreed guideline yet, not considered in JMPR

188
189
190
191
192
193
194
195
196
197
198
199
200

* These studies are normally only available in the marketing authorisation procedures and only the marker residue is measured. However, if such studies are available in a MRL procedure, they will be used in the assessment.[2]
/a: Feeding studies for pesticides only become necessary when significant feed levels (0.004 mg/kg bw or 0.1 mg/kg feed DM) are reached. Often, estimations need to be based on radioactive metabolism studies on goat and laying hens according to OECD TG 503 instead. These studies involve less animals and shorter dosing periods.
** TR=Total residue; Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017): A study of total residues should be made with the labelled active substance, administered until metabolic equilibrium in tissues is reached. The parent compound and identified metabolites (see Section 2.1.1.1) should be determined in edible tissues and products. The marker residue should be selected from this study, and the ratios marker to total residues should be established.
*** MR=Marker Residue; Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017): The minimum administration period of the additive should be 28 days, for animals for fattening for the 28 days prior to slaughter. The samples should be collected at the end of the administration period. Measurements of the marker residue concentration (MRC) should use a validated analytical method with sufficient sensitivity.

201 # Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017): For those additives in which the consequences of the rate of
202 depletion on residue concentration are needed (e.g. when MRLs are considered necessary), residues in tissues should be measured at additional sampling points after withdrawal
203 (preferably three), spaced according to the rate of depletion from tissues. The same number of animals as listed in ** and *** applies for each time point, respectively.
204
205

206 **3.4. Exposure models used**

207 Exposure is generally estimated by combining occurrence data (residues concentration) with data for
208 consumption of the respective foods/products.

209 Different models are currently used for dietary exposure estimation in various jurisdictions and by
210 different scientific bodies. The differences lie mainly in the data and assumptions used for daily food
211 consumption (e.g. default data, empirical data, individual data/summary data) and also in the
212 summary statistic from residue distributions used as input for the RoC (e.g. median/mean, upper
213 percentile/tolerance limits). For the acute exposure, typically the food commodity/RoC combination
214 leading to the highest exposure is used.

215 **3.4.1. Veterinary medicinal Products**

216 **3.4.1.1. TMDI - Theoretical Maximum Daily Intake (EMA/CVMP)**

217 The estimate of chronic dietary exposure to residues of veterinary medicinal products is based on a
218 specific model diet for the daily intake (standard food basket (SFB)⁸ made up of 300 g of muscle, 100
219 g of liver, 50 g each kidney and fat, 1500 g milk, 100 g eggs, 20 g honey) and maximum residues of
220 concern (RoC), typically 95/95 tolerance limits (i.e the upper one-sided 95% confidence limit over the
221 95th percentile of residue concentration) or MRL (both corrected with the respective MR:TR ratio)⁹.

222 A standard body weight of 60 kg for a person is used in the calculation. This includes the assumption
223 that children are also protected by the high consumption figures.

224 No specific calculation is done for acute exposure estimates. However, the TMDI is assumed to be
225 conservative enough to also cover acute exposure (the term ADI is generally used, although, strictly
226 speaking, the pharmacological ADI is most often based on an acute endpoint).

227 **3.4.1.2. GECDE/GEADE approach (JECFA)**

228 For assessment of veterinary medicinal products by JECFA, the chronic dietary exposure model used is
229 the Global Estimate of Chronic Dietary Exposure (GECDE). The GECDE uses the median residue
230 concentration combined with two different types of consumption estimates to estimate chronic
231 exposure from foods in relation to which MRLs exist or are being sought. The approach assumes that,
232 in the longer term, an individual would be a high-level consumer of only one category of food and that
233 consumption of the other foods would remain at the population mean.

234 The GECDE is calculated from the sum of the highest single food dietary exposure (computed using the
235 highest reliable percentile (HRP) consumption of each food containing the residues of interest) plus the
236 population mean dietary exposure from all the other relevant foods.

237 While the GECDE initially specified the use of the 97.5th percentile consumer, as a measure of an
238 individual with habitually high consumption of a single food, this percentile is inappropriate when the
239 number of consumers of a food is small. The HRP is the highest percentile that is consistent with the
240 reported number of consumers and may be the 97.5th, 95th, 90th or 50th percentile. The consumption

⁸ For pigs, Fat = "Fat and skin in natural proportions"; For poultry, SFB = 300 g of muscle, 100 g of liver, 10 g of kidney and 90 g of "Fat and skin in natural proportions"; For fish, SFB = 300 g of muscle and skin in natural proportions

⁹ For reasons of simplicity and to ensure better comparability across models no such corrections for the RoC acc. to MR:TR ratios have been made in the example calculations in Section 4

241 data are derived from the FAO/WHO Chronic Individual Food Consumption¹⁰ – summary statistics
242 (CIFOCoss).

243 The GECDE uses the highest consumer HRP, and highest population mean food consumption figures
244 across all surveys in CIFOCoss. Since 2017, country/survey specific estimates of chronic dietary
245 exposure, based on the GECDE methodology, have also been derived.

246 Possible population subgroups of concern, such as women of childbearing age, infants and children,
247 can be considered, as CIFOCoss contains food consumption data for a range of population subgroups.

248 The CIFOCoss database currently contains summary statistics of 289 survey/population groups from
249 32 countries, with further studies added on an ongoing basis. To be included in CIFOCoss, a food
250 consumption survey must have collected food consumption data from individuals on at least two
251 separate days.

252 The GECDE uses median RoC values as the concentration inputs for dietary exposure calculations.

253 In summary, the GECDE is the highest exposure calculated using the HRP consumption for a single
254 food selected from all the foods plus the mean dietary exposure from all the other relevant foods.¹¹

255 The Global Estimated Acute Dietary Exposure (GEADE), is an explicit estimate of acute dietary
256 exposure. The GEADE considers high-level exposure from each relevant food of animal origin,
257 individually. The concurrent occurrence of the selected high residue concentration in each food to
258 which a consumer might be exposed (e.g., an MRL or high residue concentration derived from
259 depletion studies, such as the upper one-sided 95% confidence limit over the 95th percentile residue
260 concentration) is combined with a high daily consumption (97.5th percentile, FAO/WHO large portion
261 database) of that food (meat, offal, milk, others). In cases where there is insufficient data to derive a
262 percentile, the maximum consumption may be used to obtain a worst-case exposure estimate. When
263 calculating the GEADE, instead of the amounts of food consumed set out in a model diet, more detailed
264 consumption data are used to estimate acute dietary exposure. The GEADE is reported as the highest
265 of the individual estimates for the relevant foods of animal origin. The GEADE is then used to calculate
266 the percentage exposure of the ARfD.

267 **3.4.2. Feed Additives**

268 **3.4.2.1. FACE Tool approach (EFSA)**

269 The FACE calculator¹² was developed by EFSA and is used to estimate chronic and acute dietary
270 exposure to residues of feed additives and their metabolites present in food of animal origin. The tool
271 relies on food consumption data collected from EU Member States (stored in the EFSA Comprehensive
272 European Food Consumption Database¹³). The database includes consumption data for foods as
273 consumed, such as composite foods (e.g. pizza) and other single foods or ingredients (e.g. cheese).
274 Although Member States are encouraged to disaggregate consumption of composite food into single
275 components, the level of disaggregation may differ among dietary surveys. As some of these data
276 cannot be used in exposure assessment when the occurrence data are measured in raw primary
277 commodities (RPCs), EFSA converted the Comprehensive Database into a new database (RPC
278 Consumption Database), where both RPC and RPC derivatives (RPCD) data are present, using the

¹⁰ mainly includes composite dishes, household recipes are commonly disaggregated into the main ingredients (e.g. whole pasta, cheese) but rarely to the RPC (e.g. grains, milk)

¹¹ http://www.fao.org/fileadmin/user_upload/agns/pdf/jecfa/Dietary_Exposure_Assessment_Methodologies_for_Residues_of_Veterinary_Drugs.pdf

¹² <https://dwh.efsa.europa.eu/bi/asp/Main.aspx?rwtrep=FACE>

¹³ <https://www.efsa.europa.eu/en/food-consumption/comprehensive-database>

279 RPC¹⁴ model. RPCDs are single-component foods whose nature has been physically changed through
280 processing (e.g., grilled meat, cheese, etc.). The RPC consumption data for foods of animal origin are
281 used in the FACE calculator, noting that specific consumption data for muscle are not available. Food
282 consumption of muscle is considered part of the meat consumption, which includes certain amounts of
283 trimmable fat (and skin in the case of poultry). Likewise, consumption data for kidney were very
284 limited and integrated in the consumption of other offal.

285 Residue data used for the assessment are the high-end residues of the distribution of relevant residues
286 in the food commodities (i.e. the arithmetic mean plus two standard deviations or the highest single
287 value in case of fewer than six animals)¹⁵. To account for the uncertainty on the composition of meat
288 reported above, residue concentrations for muscle and fat are applied to the intake of meat according
289 to the following proportions: 80% muscle and 20% fat for mammals and 90% muscle and 10% fat
290 (incl. skin) for poultry. The residue concentration in kidney is applied to the intake of other offal. When
291 assessing feed additives intended for multispecies use, the value for the species with the highest
292 concentration of residues in a given tissue of poultry, mammals and fish will be taken as representative
293 for that specific food commodity in all poultry, mammals and fish, respectively.

294 To obtain chronic exposure estimates, residue data are combined with the average daily consumption
295 of the corresponding food commodity, and the resulting exposures per food are summed to obtain total
296 chronic exposure at the individual level. Distributions of the individuals' exposures are estimated for
297 the different European countries and age classes, and reported using summary statistics, representing
298 mean and high-level exposure (i.e. the 95th percentile of exposure distribution). The tool also indicates
299 how different food commodities contribute to the overall exposure. Acute exposure estimates are
300 obtained similarly based on the consumption of a food commodity within a single day (instead of
301 average daily consumptions).

302 The FACE calculator contains consumption data from 33 dietary surveys, which allows to obtain
303 exposure estimates for 17 countries in 7 age classes (infants, toddlers, other children, adolescents,
304 adults, elderly and very elderly).

305 For further information, please consult "Guidance on the assessment of the safety of feed additives for
306 the consumer", EFSA Journal 2017;15(10):5022¹⁶

307 **3.4.3. Pesticides**

308 **3.4.3.1. IEDI/IESTI approach (JMPR)**

309 The assessment of residues in foods by JMPR following the use of pesticidal active substances is
310 conducted considering the long-term (chronic) and, if the substance under review has acute toxic
311 properties, the short-term (acute) dietary exposure. The consumer is considered to be adequately
312 protected when estimated dietary intake of pesticides residues do not exceed the acceptable daily
313 intake (ADI) or the acute reference dose (ARfD). Details on the methodology can be found in the 3rd
314 Revision of the FAO Manual on the Submission and Evaluation of Pesticide Residues Data¹⁷.

315 For the chronic dietary exposure assessment, the International Estimated Daily Intakes (IEDIs) are
316 estimated based on the residue definition for dietary risk assessment derived by the JMPR, which
317 includes all compounds (pesticidal active substance and their metabolites/degradates) significantly

¹⁴ <https://www.efsa.europa.eu/en/supporting/pub/en-1532>

¹⁵ <https://doi.org/10.2903/j.efsa.2017.5022>

¹⁶ <https://www.efsa.europa.eu/en/applications/feedadditives/tools>

¹⁷ <https://www.fao.org/3/i5452e/i5452e.pdf>) and in Chapter 6 of Environmental Health Criteria 240 (EHC 240,
https://cdn.who.int/media/docs/default-source/food-safety/publications/chapter6-dietary-exposure.pdf?sfvrsn=26d37b15_6

318 contributing to the risk. The IEDI Model is based on the WHO GEMS Food Cluster diets, estimating
319 average per capita consumption figures based on international trade and production statistics of
320 foods¹⁸. Occurrence input parameters are estimated by the JMPR on the basis of registered uses of
321 plant protection products with the active substance of interest. From all supervised field trial and
322 animal feed studies available, median residue concentrations are identified for each food. In addition,
323 quantitative information on the behaviour during industrial processing are taken into account. The IEDI
324 represents the sum of average exposures from all individual food items – plant and animal based –
325 expressed in µg/kg bw per day. It is compared with the ADI value of the active substance and
326 addresses the long-term (lifelong) dietary risk. No stratifications e.g. concerning sub-populations, age
327 groups, specific diets are taken into account. Also, no refinements related to use frequencies of plant
328 protection products are considered.

329 In addition, when an active substance shows acute toxic properties and an ARfD becomes necessary,
330 the International Estimate of the Short-Term Intake (IESTI) is assessed. The principles of the IESTI
331 Methodology were revised several times and the current approach is also described in the documents
332 cited for the IEDI. The IESTI addresses the dietary risk arising from a single high exposure within 24h
333 via foods. In contrast to the IEDI, actual consumption data based on national dietary surveys are
334 considered in a deterministic model consisting on three cases. The IESTI calculates the exposure using
335 4 different equations (case 1, 2a, 2b, 3) considering the amount of large portion consumed, edible unit
336 weight and the bulking/blending of the commodities, but only the case 1 and case 3 calculations are
337 considered relevant for food of animal origin. The target consumption value is defined as large portion
338 “LP”, which represents the 97.5th percentile of the portion size from all individuals which consumed the
339 respective food item (consumers only). Input parameters for the occurrence data are either the
340 highest residues (HR) observed in supervised field trial and animal feed studies for unblended
341 commodities (e.g. pieces of fruit or vegetables, meat, eggs) or the median residue for blended
342 commodities (e.g. cereal grains, pulses, oilseed, milk). Again, quantitative information on the
343 behaviour during industrial processing is considered and a variability factor is considered for some
344 cases describing the heterogeneity of residues in composite samples. The IESTI Methodology considers
345 each food commodity individually – no aggregation with other foods is foreseen. The IESTI Model
346 currently used by JMPR represents a compilation of national or supra-national IESTI models (e.g. EFSA
347 PRIMo) and LP data submitted to WHO directly. From all data available, the most critical case leading
348 to the highest exposure per kg bodyweight is identified and considered by JMPR to estimate the acute
349 dietary exposure, which is compared to the ARfD. Since the IESTI model is based on consumption data
350 sub-populations (general population, children, women in childbearing age) are specifically addressed.

351 The latest versions of the IEDI and IESTI Model used by JMPR can be obtained from the WHO GEMS
352 Food Website¹⁹.

353 In summary, JMPR uses two different approaches to assess the dietary risk for consumers. The IEDI
354 model based on trade/production statistics represents the average long-term dietary exposure over a
355 lifetime while the IESTI aims at a single high exposure event within 24h. To exclude potential dietary
356 risks for consumers, the exposure from both approaches should not exceed the ADI and/or the ARfD.

357 **3.4.3.2. PRIMo approach (EFSA)**

358 Since 2007, the EFSA Pesticide Residue Intake Model (PRIMo) is the standard tool used at EU level to
359 perform the dietary risk assessment for pesticide residues in food of plant and animal origin, i.e. to
360 estimate the short- and long-term dietary exposure and compare those exposures to the relevant

¹⁸ <https://www.who.int/data/gho/samples/food-cluster-diets>

¹⁹ <https://www.who.int/teams/nutrition-and-food-safety/databases/global-environment-monitoring-system-food-contamination>

361 toxicological reference values (ADI and ARfD, respectively). It is a deterministic model that uses
362 internationally agreed methodologies for the assessment of pesticide residues and it is mainly used
363 under the regulatory framework of Regulation (EC) No 396/2005 and Regulation (EU) No 1107/2009.

364 Revision 4 of PRIMo is currently under development by EFSA. As in the case of FACE, PRIMo 4 will rely
365 on food consumption data from the RPC Consumption Database, where both RPC and RPC derivatives
366 (RPCD) data are present. RPCDs are single-component foods whose nature has been physically
367 changed through processing (e.g. grilled meat, cheese, etc.).

368 Unlike FACE, in PRIMo 4 the classification of foods is more refined, allowing to also perform an
369 assessment at the level of RPCDs and a further distinction between different types of mammals (i.e.
370 cattle, goats, sheep and pigs).

371 Within the chronic exposure assessment, occurrence data are combined with the average daily amount
372 of food consumed and the exposure calculated for the different commodities is then summed up by
373 subject. Summary statistics (i.e. mean, percentiles) are then calculated for the total population of the
374 different European countries, surveys and age classes. Although in the area of pesticide residues risk
375 managers now mainly refer to the mean exposure, EFSA will introduce the use of the highest reliable
376 percentile (HRP) for chronic risk assessment in PRIMo 4, to promote possible harmonisation with other
377 domains of activity. The HRP is the highest percentile of exposure that can be obtained based on the
378 number of subjects included in the dietary survey. While in FACE the HRP is only derived up to the 95th
379 percentile, in the case of pesticides HRP estimates are derived up to the 97.5th. However, the mean
380 exposure estimates will still be reported in the outputs.

381 Acute estimates are obtained similarly, firstly applying the International Estimated Short-Term Intake
382 (IESTI) formulae²⁰ and considering the exposure to a certain commodity consumed within a single day.
383 The IESTI calculates the exposure using 4 different equations (case 1, 2a, 2b, 3) considering the
384 amount of large portion consumed, edible unit weight and the bulking/blending of the commodities,
385 but only the case 1 and case 3 calculations are considered relevant for food of animal origin. The HRP
386 (up to the 97.5th percentile) of exposures based on the consuming days is then calculated for each
387 RPCD, dietary survey and age class separately. The most critical estimate among the different RPCDs
388 is considered for decision making.

389 As for the FACE calculator, PRIMo 4 will contain consumption data from 33 dietary surveys, which
390 allows to obtain exposure estimates for 17 countries in 7 age classes (infants, toddlers, other children,
391 adolescents, adults, elderly and very elderly).

²⁰ https://www.who.int/foodsafety/chem/guidance_for_IESTI_calculation.pdf

3.4.4. Summary of approaches EMA, EFSA, JECFA, JMPR

	Veterinary Medicinal Products		Feed Additives	Pesticides		
	EMA	JECFA	EFSA	EFSA	JMPR	
Commodities	Raw commodities	Raw commodities (no incl. of processed commodities at the moment)	Raw commodities (processed foods converted to raw primary commodity (RPC))	Raw commodities (processed foods converted to raw primary commodities (RPCs) and raw primary commodity derivatives (RPCDs))	Mainly raw commodities (processed foods converted to raw commodity (RPC)). Major processed foods (e.g. juices, wine, beer) considered processed.	
Consumption data	Standard Food basket	EU food consumption data (summary statistics) (g/person) (CIFOCOs EU data)	EU food consumption data (individual dietary records) (g/kg bw)	EU food consumption data (individual dietary records) (g/kg bw)	GEMS Food Cluster diets (trade/production statistics) (g per capita per day)	
Age classes considered	Adult (60 kg)	General (total) population (subgroups if needed based on toxicology)	Infants, toddlers, other children, adolescents, adults, elderly and very elderly	Infants, toddlers, other children, adolescents, adults, elderly and very elderly	Adult (60 to 65 kg)	
Occurrence data	Residue studies target animal	Residue studies target animal	Residue studies target animal	Residue studies target animal	Residue studies target animal	
residue definition/residue for dietary risk assessment	<i>Total residues (by default, exceptions possible when</i>	Total residues (by default, exceptions possible when toxicological properties	<i>Depending on the nature of the feed additive, total residues and/or marker residue²¹ (by</i>	Enforcement: Suitable marker residue (pref. parent or single substance, analysed by multi-methods, same in all commodities)	Enforcement: Suitable marker residue (pref. parent or single substance, analysed by multi-methods, same in all commodities)	

²¹ *Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017): For the following substances, the requirement for residue data is limited to marker residue (Section 2.1.2.2) concentrations comparing the tissue/products levels in an untreated group and in the group supplemented with the highest proposed concentration without a withdrawal time:

- substances which are a natural constituent of body fluids or tissues or are naturally present in food or feedingstuffs if the use of the additive substantially increases the intake or tissue retention;

		<i>toxicological properties residue are well-defined)</i>	residue are well-defined)	<i>default, exceptions possible when toxicological properties residue are well-defined)</i>	Risk Assessment: Set of defined substances covering a significant amount of the residue (currently parent and major metabolites, if quantitatively relevant, plus substances with known higher toxicity. In addition, compounds with individual HBGVs may be assessed in separate residue definition (RDs.)	Risk Assessment: Set of defined substances covering a significant amount of the residue (currently parent and major metabolites, if quantitative relevant, plus substances with known higher toxicity. In addition, compounds with individual HBGVs may be assessed in separate RDs.)
Input occurrence data	chronic	MRL or UTL (95/95 upper tolerance limits)	Median	Mean + 2xSD or highest residue (dep. on the animal number)	Mean	Median/mean
	acute	Not applicable ²²	Upper 95/95 residue	Mean + 2xSD or highest residue (dep. on the animal number)	For unblended commodities (i.e. tissues & eggs), highest residue (HR) at the maximum livestock dietary burden. For blended commodities (i.e. milk), mean residue at the maximum livestock dietary burden	highest residue (HR) for unblended commodities (e.g. fruits, vegetables, tissues) and median/mean residue (STMR) for blended commodities (juice, grains, milk etc.)
Exposure output	(chronic)	TMDI (sum of MRL x food baskets components)	GECDE (here based on EU data) the highest exposure from	Distribution of chronic exposure estimates for the total population, characterised by	Distribution of chronic exposure estimates for the total population, characterised by the mean and 97.5 th percentile	IEDI (sum of all food commodities using mean/median residue and average consumption)

- for colourants which add colour to food of animal origin;
- 'vitamins, pro-vitamins and chemically well-defined substances, having similar effect' that have a potential for accumulation in the tissues/products which are not already authorised;
- 'compounds of trace elements' not already authorised;
- additives already authorised in food for which a health-based guidance value is established.

²² Normally no acute estimate is done, however, as TMDI is assumed to be conservative enough also for acute endpoints, the same input parameters as for chronic estimates are used here.

			one animal product (highest 97.5th percentile or other HRP, consumers only) plus mean highest total population exposure from all other products	the mean and 95 th percentile exposure (or other HRP) per country and age class	exposure (or other HRP) per country and age class	
	acute	Not applicable ¹¹	GEADE The concurrent occurrence of the selected high residue concentration in each food to which a consumer might be exposed is combined with a high daily consumption (97.5th percentile) of that food. The highest exposure of an individual food is selected	Distribution of acute exposure estimates for consumers only, characterised by the mean and 97.5 th percentile exposure (or other HRP) per country, age class and RPC.	Distribution of acute exposure estimates for consumers only, characterised by the mean and 97.5 th percentile exposure (or other HRP) per country, age class and RPC.	IESTI (if ARfD necessary based on tox. effects), single commodity wise
Estimating exposure from multiple species/products	chronic	TMDI includes the highest residue concentration for muscle, liver, kidney and fat (from all species) + milk + eggs + honey	Combined GECDE over all animal species and food commodity (meat+ fat + edible offal + milk + eggs + honey)	Combined exposure, e.g. as the sum of consumption from all animals within a group (e.g. cattle, sheep, etc...) using occurrence data at the highest residue	Combined over all animal species and food commodities (i.e. meat+ fat + edible offal + milk + eggs + fish + honey)	IEDI always considers combined exposure from all animal and plant based foods

				concentration observed (e.g. highest mammal) + consumption from all animals within another group (e.g. poultry/chicken or fish) + milk + eggs + honey		
	acute	Not applicable ¹¹	Acute exposure is estimated for each species and product separately; the most critical estimate is selected and considered sufficiently protective to cover all products and species.	Acute exposure is estimated for each species and product separately; the most critical estimate is selected and considered sufficiently protective to cover all products and species.	Acute exposure is estimated for each species and product separately; the most critical estimate is selected and considered sufficiently protective to cover all products and species.	Acute exposure is estimated for each species and product separately; the most critical estimate is selected and considered sufficiently protective to cover all products and species.
Other dietary exposure estimates²³		None	YES short term (if needed based on toxicology) Injection site	None	None	None
Hazard endpoint	chronic	ADI	ADI (specific endpoints for subgroups, if necessary)	ADI or UL (depending on the nature of the feed additive)	ADI	ADI
Hazard endpoint	acute	None (however, pharm/micro ADI)	ARfD	ARfD	ARfD	ARfD

²³ Not falling under current mandate. Mentioned for completeness.

393

Hazard endpoint	short term	none	short-term endpoint(s), as required	none	none	ADI (if short-term effects are identified in tox. studies)
------------------------	------------	------	-------------------------------------	------	------	--

394 **4. Exercise to compare the estimates of dietary exposure** 395 **from different models**

396 To explore and better understand quantitative differences between the various exposure models
397 described above (i.e. TMDI, FACE, PRIMo 4²⁴ and GECDE/GEADE, IEDI/IESTI), different sets of residue
398 data were applied. These data were derived from real residue studies of VMPs (slightly modified e.g.
399 filling data gaps with simulations, for the calculations to generate sufficient data to conduct the
400 estimates). For each dataset (i.e. bovine meat and offal as well as milk, chicken meat and offal as well
401 as eggs, fish and honey), anonymised (i.e. deleting any information relating to the substance or
402 protected data, which allow to identify the substance and or the product) individual residue data, as
403 well as summary statistics of these data, were provided to the experts, who then conducted the
404 estimates for 'their' dietary exposure models (i.e. EFSA experts for FACE and PRIMo 4, JECFA- experts
405 for GECDE/GEADE, JMPR experts for IEDI/IESTI and EMA experts for TMDI). In all exercises, the so-
406 called "marker residue" (parent compound) was used without considering any corrections for
407 potentially relevant metabolites and marker/total ratios (residues of concern, respectively) or other
408 factors^{25,26}. Although this is perfectly acceptable for relative quantitative comparisons of the models,
409 such factors would need to be taken into account in a final exposure estimate used in the risk
410 characterisation.

411 It is noted that certain elements in the design of residue studies may differ between the veterinary,
412 feed additive and pesticide field which may influence the type and amount of data available. For a
413 direct comparison of the output of the various exposure models the study design is not considered
414 relevant and therefore it is acceptable to use the residue data from VMPs in this exercise. However, the
415 question of study design can play a role in connection with the type/quantity and choice of available
416 input data.

417 **4.1. Model data sets**

418 Residue depletion data from the "Guideline on the determination of withdrawal periods for edible
419 tissues" (EMA/CVMP/SWP/735325/2012) and from other residue depletion studies (for veterinary
420 medicinal products) were used as model data sets.

421 Measures of central tendency and measures of variation as listed in the table below were derived from
422 the residue depletion data in relevant edible tissues as a basis for use in the dietary exposure models.

423 Additional values for meat were calculated based on residue concentrations in muscle and fat at
424 proportions of 80% and 20%, respectively to be used with the FACE and PRIMo 4-models.

²⁴ PRIMo4 is currently under development

²⁵ As these factors are applied multiplicatively and they would not change the relative comparisons.

²⁶ Consideration of metabolites and various toxicologically derived residue definitions, is not part of the calculations of Chapter 4, but needs to be discussed in view of further harmonization of risk characterization models at a later stage.

425 **Table 2: Summary statistics of residue data for bovine meat and offal**

Tissue/ Day	Ari. Mean* µg/kg	+/- SD µg/kg	Mean + 2 SD**** µg/kg	Geom. Mean** µg/kg	+/- SD µg/kg	Median µg/kg	Upper 95/95 Tolerance*** µg/kg	Maximum µg/kg
Liver								
Day 7	119.1	56.2	231.5	102.6	1.9	127.2	797.5	198.0
Day 14	32.5	19.1	70.7	23.6	3.1	25.9	232.1	60.8
Day 21	19.7	29.6	78.9	9.9	3.3	9.0	74.9	108.0
Day 28	4.9	4.4	13.7	3.2	2.7	3.4	26.8	13.5
Kidney								
Day 7	29.8	17.1	64	24.9	2.0	28.15	133.9	60.8
Day 14	8.7	6.4	21.5	6.3	2.5	7.9	45.2	20.3
Day 21	4.4	3.6	11.6	3.4	2.1	2.3	18.5	11.3
Day 28	1.7	1.1	3.9	1.5	1.7	1.0	8.4	4.5
Fat								
Day 7	177.3	104.4	386.1	151.8	1.8	176.65	969.7	450.0
Day 14	29.2	23.3	75.8	17.7	3.7	23.65	260.1	78.8
Day 21	11.7	11.0	33.7	8.3	2.5	9	77.7	40.5
Day 28	5.0	4.0	13.0	3.5	2.7	4.5	25.8	13.5
Muscle								
Day 7	15.5	7.7	30.9	13.2	2.0	16.3	65.9	24.4
Day 14	5.1	3.6	12.3	4.0	2.2	5.4	24.0	13.6
Day 21	2.4	2.2	6.8	1.9	1.9	2.2	10.4	9.0
Day 28	1.2	0.5	2.2	1.1	1.3	1.0	5.0	2.8
Meat****								
Day 7	47.86		101.9					109.52
Day 14	9.92		25.0					26.64
Day 21	4.26		12.1					15.3
Day 28	1.96		4.4					4.94

426 *N=12 treated animals per day; *arithmetic mean, ** geometric mean, ***95% tolerance level with 95%*
 427 *confidence, calculated via linear regression analysis as described in the Guideline on determination of withdrawal*
 428 *periods for edible tissues²⁷*
 429 ***** For calculation with the FACE and PRIMo 4-model, residue concentrations in muscle and fat were applied to*
 430 *the intake of meat according to the following proportions: mammals 80% muscle and 20% fat.*

²⁷<https://www.ema.europa.eu/en/approach-towards-harmonisation-withdrawal-periods-edible-tissues>

431 **Table 3: Summary statistics of residue data for milk**

Hours	Ari. Mean* µg/kg	+/- SD µg/kg	Mean + 2 SD**** µg/kg	Geom. Mean** µg/kg	+/- SD µg/kg	Median µg/kg	Upper 95/95 Tolerance*** µg/kg	Maximum µg/kg
24	0.9	0.8	1.44	0.7	3.0	0.9	No of animals too low	1.4
36	3.6	4.3	6.62	1.9	5.7	3.6	No of animals too low	6.6
48	4.3	0.1	4.5	3.3	2.2	3.3	20.6	11.4
60	4.9	0.1	5.1	4.0	1.9	3.9	19.7	11.3
72	5.0	0.5	6.0	4.2	1.9	4.4	18.7	11.0
84	4.5	0.1	4.7	4.0	1.7	4.2	13.9	9.2
96	3.8	0.4	4.6	3.4	1.6	3.4	10.4	8.6
120	2.8	0.2	3.2	2.6	1.5	2.7	7.1	6.9
144	2.5	0.2	2.9	2.2	1.6	2.3	6.7	5.5
168	1.9	0.2	2.3	1.8	1.5	1.7	4.9	3.4
192	1.3	0.0	1.3	1.2	1.6	1.2	3.5	2.4
216	0.9	0.1	1.1	0.8	1.6	0.8	2.5	2.0

432 *N=20 treated animals per day (at 24 and 36 hours only N=2 treated animals); *arithmetic mean, ** geometric*
433 *mean, ***95% tolerance level with 95% confidence, calculated as described in the Guideline on determination of*
434 *withdrawal periods for milk²⁸*
435 ***** If the number of animals is < 6, the highest value is used.*

²⁸ <https://www.ema.europa.eu/en/determination-withdrawal-periods-milk#current-version---currently-under-revision,-see-below-section>

Table 4: Summary statistics of residue data for chicken meat and offal

Tissue/ Day	Ari. Mean* µg/kg	+/- SD µg/kg	Mean + 2 SD**** µg/kg	Geom. Mean** µg/kg	+/- SD µg/kg	Median µg/kg	Upper 95/95 Tolerance*** µg/kg	Maximum µg/kg
Liver								
Day 1	1301.1	341.6	1984.3	1266.7	1.3	1219.0	2268.0	1963.0
Day 2	1002.5	231.3	1465.1	980.3	1.3	946.6	1808.2	1345.0
Day 4	694.9	108.1	911.1	688.0	1.2	679.6	1160.0	846.0
Day 7	378.4	124.7	627.8	363.1	1.4	365.1	614.0	621.1
Day 10	188.4	80.1	348.6	177.0	1.4	151.9	334.5	348.6
Kidney								
Day 1	841.2	192.8	1226.8	823.3	1.2	784.1	1470.0	1203.0
Day 2	661.1	168.7	998.5	645.5	1.3	630.3	1176.3	1013.0
Day 4	448.7	78.6	605.9	443.1	1.2	417.9	760.3	563.9
Day 7	242.9	74.5	391.9	233.9	1.3	236.5	407.0	380.1
Day 10	129.8	60.0	249.8	120.8	1.5	101.8	224.3	253.5
Skin + Fat								
Day 1	1275.8	204.6	1685	1261.1	1.2	1309.0	2360.5	1526.0
Day 2	984.8	216.7	1418.2	966.2	1.2	887.3	1877.7	1336.0
Day 4	695.0	251.1	1197.2	656.7	1.4	667.5	1200.7	1036.0
Day 7	332.6	91.5	515.6	322.7	1.3	319.4	634.6	508.2
Day 10	197.7	103.1	403.9	181.2	1.5	164.5	346.5	418.1
Muscle								
Day 1	108.2	25.2	158.6	105.8	1.3	100.0	175.8	152.2
Day 2	84.7	19.8	124.3	82.7	1.3	87.2	145.9	113.8
Day 4	59.4	10.8	81	58.6	1.2	55.1	101.4	76.2
Day 7	39.8	8.2	56.2	39.1	1.2	39.6	60.4	49.7
Day 10	21.4	8.8	39	20.3	1.4	17.4	36.9	40.4
Meat****								
Day 1	224.96		311.2					289.58
Day 2	174.71		253.7					236.02
Day 4	122.96		192.6					172.18
Day 7	69.08		102.1					95.55
Day 10	39.03		75.5					78.17

437 *N=7 treated animals per day; *arithmetic mean, **geometric mean, ***95% tolerance level with 95% confidence,*
438 *calculated via linear regression analysis as described in the Guideline on determination of withdrawal periods for*
439 *edible tissues²⁷*

440 ***** For calculation with the FACE and PRIMo 4-model, the residue concentration in muscle and fat will be applied*
441 *to the intake of meat according to the following proportions: poultry 90% muscle and 10% skin+fat.*

442 **Table 5: Summary statistics of residue data for eggs**

	Number of samples	Ari. Mean* µg/kg	+/- SD µg/kg	Mean + 2 SD**** µg/kg	Geom. Mean** µg/kg	+/- SD µg/kg	Median µg/kg	Upper 95/95 Tolerance*** µg/kg	Maximum µg/kg
Day		µg/kg	µg/kg		µg/kg	µg/kg	µg/kg	µg/kg	µg/kg
5	14	420.2	125.5	671.2	396.9	1.5	452.6	1071	570.1
6	15	519.7	109.6	738.9	504.4	1.3	525.4	1038.8	667.4
7	12	576.1	145.9	867.9	551.2	1.4	571.5	1429.7	763.1
8	14	552.4	65.9	684.2	549	1.1	539.4	741.8	703.5
9	11	546.4	113.1	772.6	535.6	1.2	555.2	971	707.3
10	14	594.5	83.8	762.1	589.1	1.2	579.7	849.8	730.0
11	14	709.2	120.1	949.4	699.5	1.2	694.9	1103.1	899.6
12	14	783.9	101.2	986.3	777.9	1.1	758.6	1091.8	958.0
13	12	812.6	115.1	1042.8	805.6	1.1	790.4	1167.9	1072.0
14	13	828.4	133.3	1095	818.9	1.2	784	1245.5	1065.0
15	14	734.5	114.2	962.9	725.8	1.2	748	1110.4	915.5
16	15	621.1	147.5	916.1	596.6	1.4	641.1	1397	853.8
17	12	502.9	130.7	764.3	482.6	1.4	511.3	1177.5	671.4
18	15	387.2	147.2	681.6	357	1.5	430.6	1095.2	636.9

443 *arithmetic mean **Geometric mean and standard deviation are estimated by Maximum Likelihood Optimization
 444 assuming a log-normal distribution of residues censored at LOQ. This is only applicable to time points with values
 445 BLQ.; ***95% tolerance level with 95% confidence, calculated via linear regression analysis as described in the
 446 Guideline on determination of withdrawal periods for milk²⁸
 447

448 **Table 6: Summary statistics of residue data for fish (n=10 samples per day)**

Tissue/ Day	Ari. Mean* µg/kg	+/- SD µg/kg	Mean + 2 SD**** µg/kg	Geom. Mean** µg/kg	+/- SD µg/kg	Median µg/kg	Upper 95/95 Tolerance*** µg/kg	Pointwise 95/95 UTL **** µg/kg	Maximum µg/kg
Muscle									
Day 1	307.2	60.3		302.7	1.2	296.5	512.2	501.6	463.0
Day 7	48.0	8.9		47.2	1.2	48.9	81.8	82.5	64.7
Day 14	6.3	2.0		6.0	1.4	6.1	10.3	15.1	10.5
Skin									
Day 1	249.4	46.4		245.9	1.2	242.0	481.3	408.2	355.0
Day 7	36.2	7.7		35.4	1.3	36.9	70.0	68.0	49.1
Day 14	4.4	1.7		4.1	1.5	4.1	8.0	14.3	7.6
Filet (Muscle+Skin)									
Day 1	301.9	54.2	410.3	298.2	1.2	290.5	526.8	475.7	437.0
Day 7	50.0	11.7	73.4	48.7	1.3	51.0	84.3	97.6	73.5
Day 14	6.3	2.0	10.3	6.0	1.4	6.2	10.6	15.3	9.6

449 *arithmetic mean; ** geometric mean; ***95% tolerance level with 95% confidence, calculated via linear
 450 regression analysis as described in the Guideline on determination of withdrawal periods for edible tissues²⁷;
 451 ****95% tolerance level with 95% confidence, calculated as described in the Guideline on determination of
 452 withdrawal periods for milk²⁸
 453

454 **Table 7: Summary statistics of residue data for honey**

Location/ Treatment/ Day	Number of samples	Ari. Mean* µg/kg	+/- SD µg/kg	Mean + 2 SD**** µg/kg	Geom. Mean** µg/kg	+/- SD µg/kg	Median µg/kg	Upper 95/95 Tolerance** * µg/kg	Maximum µg/kg
TG1 (B)									
Day 7	4	1365.5	810.6	2986.7	1129.1	2.2	1383.3	65144.3	2323.6
Day 16	4	1017.0	737.5	2492.0	695.9	3.4	1025.5	354603.4	1896.2
TG1 (D)									
Day 7	6	1465.1	1067.4	3599.5	988.9	3.1	1567.0	63562.9	2863.1
Day 16	6	1237.9	1033.7	3305.3	803.4	3.2	998.3	58332.7	2694.4
TG2 (B)									
Day 7	5	1674.0	741.6	3157.2	1527.0	1.7	1471.6	12633.9	2589.9
Day 16	5	1613.0	605.1	2823.2	1540.3	1.4	1412.1	5993.4	2671.7
TG2 (D)									
Day 7	5	1211.8	792.5	2796.8	974.1	2.2	997.8	28660.9	2353.7
Day 16	5	1066.3	713.4	2493.1	827.4	2.4	825.4	34557.5	1955.8

455 *B, D = location; TG = different types of hives; *arithmetic mean; ** geometric mean, ****95% tolerance level with*
 456 *95% confidence, calculated as described in the Guideline on determination of withdrawal periods for milk*²⁸
 457

458 **4.2. Chronic Exposure**

459 To derive estimates for chronic exposure, TMDI uses the consumption data from the SFB and the
 460 upper 95/95 tolerance interval of the residue depletion data (3.4.1).

461 Both EFSA models, FACE and PRIMo 4, use the individual consumption figures from the RPC
 462 consumption database. For the occurrence data, the first uses the mean +2 SD from the residue
 463 depletion data (3.4.2.1.), whereas the second uses the arithmetic mean of the residue data (3.4.3.2.
 464). Although PRIMo 4 allows to calculate exposure for the different types of mammals (i.e. equine,
 465 sheep, goat, swine, bovine, other farmed terrestrial animals), the calculations presented in this section
 466 were performed for all mammals. The food classification used in PRIMo also makes a distinction
 467 between liver, kidney and other offal and slaughtering products. For the latter category, the residue
 468 concentration was assigned taking the highest occurrence value from liver and kidney.

469 Median residue concentrations were used to calculate the GECDE. At all time points, dietary exposure
 470 estimates based on liver highest reliable percentile was the highest contributor to estimated dietary
 471 exposure. For all other food commodities, the highest mean was used (3.4.1.2.). To allow for better
 472 comparability, only European food consumption data were used for this exercise.

473 The IEDI uses mean/median residue values and processing factors (if applicable). Furthermore, the
 474 IEDI is based on 17 GEMS food cluster diets. Each diet contains individual values for each food
 475 commodity, but only the totals from each cluster are considered for chronic exposure. In the following
 476 tables, the highest exposure per commodity from European clusters is listed. However, if another
 477 (Non-European) cluster results in higher exposure the highest exposure estimate from all 17 clusters
 478 (as normally used in IEDI) is given in brackets (3.4.3.1.).

479 **4.2.1. Bovine meat and offal and milk**

480 **Meat and offal**

481 Chronic dietary exposure estimates for bovine meat and offal calculated based on the five models are summarised in Table 8.

482 *Table 8: Chronic exposure estimates for bovine (mammals) meat and offal expressed as µg/kg bw per day*

Day	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old			
7	2.58	0.84	1.04	1.05	0.93	0.67	0.47	0.45	0.47	0.54	0.60	0.49	0.43	0.29	0.21	0.18	0.18
14	0.76	0.20	0.24	0.26	0.21	0.16	0.12	0.10	0.09	0.11	0.11	0.10	0.09	0.06	0.05	0.04	0.04
21	0.26	0.11	0.13	0.13	0.11	0.08	0.06	0.07	0.04	0.05	0.05	0.04	0.04	0.03	0.02	0.01	0.02
28	0.10	0.04	0.04	0.04	0.04	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01

483 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights, to note: PRIMo 4 normally distinguishes between
 484 cattle and other mammalian species, however for better comparison with FACE, the values for mammalian species were used here; 3) average bodyweights are assumed;
 485 green-red = lowest-highest value in a row; in bold: highest value in a column
 486

487 From Table 8 it can be seen that the highest values at all time points result from the TMDI model. Concentrations at each time point are at least 2 times
 488 above concentrations resulting from all other models/age groups, showing that TMDI leads to very conservative estimates for edible tissues. This may largely
 489 be attributed to the upper 95/95 tolerance limit used in the TMDI calculation. As shown in Table 2, the upper 95/95 tolerance levels were up to 3 times
 490 higher than the mean + 2 SD (as used by FACE), up to 9-fold higher than the mean (as used by PRIMo 4) and up to 11-fold the median (as used by GECDE
 491 and IEDI).

492 The second highest values were obtained using the FACE model for the groups of toddlers and children ≥36 months to <10 years. Results from GECDE and
 493 IEDI calculations were roughly one order of magnitude lower than results from the FACE model. PRIMo 4 results in approximately half of the exposure value
 494 of FACE in all subgroups. Looking at the residue concentrations used for the estimation, the mean used by PRIMo is about half of the value of mean + 2 SD
 495 as used by FACE, explaining the differences between these two models.

496 The different consumption assumptions used might also contribute to the differences mentioned above; TMDI uses the sum of residue concentrations for all
 497 relevant tissues in a standard food basket (i.e. it assumes that each person consumes the same amount from each food commodity each day). In contrast,
 498 the FACE and PRIMo 4 tools consider food commodities at an individual level, which means, for example, that a person may eat a considerable amount of
 499 meat but not necessarily eat liver (or the other way around). The GECDE is the sum of the highest dietary exposure calculated using the highest reliable
 500 percentile (HRP) consumption of a single food, plus the population mean dietary exposure from all the other relevant foods. IEDI uses supply (or portion) in
 501 g/d and person of each food obtained by dividing the quantity for each country by its population from economy statistics (food production, import, export).

502 **Milk**

503 The outcome of the chronic dietary exposure estimates for milk with the five models are summarised in Table 9.

504 **Table 9: Chronic exposure estimates for bovine (mammals) milk expressed as µg/kg bw per day**

Hrs	TMDI	FACE							PRIMo 4							GECDE	IEDI
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
24	n.d.	0.18	0.18	0.23	0.08	0.05	0.04	0.05	0.12	0.12	0.15	0.06	0.04	0.03	0.04	0.02	0.01
36	n.d.	0.82	0.81	1.07	0.39	0.22	0.19	0.22	0.49	0.46	0.59	0.24	0.16	0.12	0.14	0.07	n.c.
48	0.52	0.56	0.55	0.72	0.26	0.15	0.13	0.15	0.59	0.55	0.70	0.28	0.19	0.15	0.17	0.06	0.03
60	0.49	0.63	0.62	0.82	0.30	0.17	0.15	0.17	0.67	0.63	0.80	0.32	0.22	0.17	0.19	0.07	n.c.
72	0.47	0.74	0.73	0.97	0.35	0.20	0.17	0.20	0.68	0.64	0.82	0.33	0.23	0.17	0.20	0.08	0.04
84	0.35	0.58	0.58	0.76	0.28	0.15	0.14	0.15	0.61	0.58	0.73	0.29	0.20	0.15	0.18	0.08	n.c.
96	0.26	0.57	0.56	0.74	0.27	0.15	0.13	0.15	0.52	0.49	0.62	0.25	0.17	0.13	0.15	0.06	0.03
120	0.18	0.40	0.39	0.52	0.19	0.10	0.09	0.10	0.38	0.36	0.46	0.18	0.13	0.10	0.11	0.05	n.c.
144	0.17	0.36	0.35	0.47	0.17	0.10	0.08	0.09	0.34	0.32	0.41	0.16	0.11	0.09	0.10	0.04	0.02
168	0.12	0.29	0.28	0.37	0.14	0.08	0.07	0.08	0.26	0.24	0.31	0.12	0.09	0.07	0.07	0.03	0.02
192	0.09	0.16	0.16	0.21	0.08	0.04	0.04	0.04	0.18	0.17	0.21	0.08	0.06	0.04	0.05	0.02	0.02
216	0.06	0.14	0.13	0.18	0.06	0.04	0.03	0.04	0.12	0.12	0.15	0.06	0.04	0.03	0.04	0.02	0.01

505 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; to note: PRIMo 4 normally distinguishes between
 506 cattle and other mammalian species, however for better comparison with FACE, the values for mammalian species were used here; 3) average bodyweights are assumed;
 507 green-red = lowest-highest value in a row; in bold: highest value in a column;
 508 n.c. = not calculated

509 For milk, the TMDI did not result in the highest dietary exposure values expressed on a µg/kg bw base.
510 The highest dietary exposure values were derived for children up to an age of 10 years (approximately
511 2 times higher compared to TMDI results), calculated with the FACE model. Adolescents up to 18 years
512 have dietary exposure values similar to the estimations based on the TMDI model.

513 Also for milk, the residue concentrations used by TMDI (upper 95/95 tolerance) were higher (up to 4.5
514 fold) compared to other models, e.g. the concentration used by FACE (mean + 2 SD), up to 5-fold the
515 concentrations (mean) used for PRIMo 4 and 6 fold higher than the median used by GECDE (see Table
516 3). This may to a large extent explain the higher exposure value for the TMDI compared to GECDE,
517 FACE and PRIMo 4-models for adolescents, adults, elderly and very elderly as the consumption figures
518 do not differ significantly for these age groups. On a bodyweight basis, children consume much more
519 milk than adults, and the consumption figure was also much higher compared to the value used in
520 TMDI (which uses a standard assumption of 25 g milk per kg bw for a 60 kg adult).

521 The really low exposure levels for IEDI cannot be explained by different residue input values, but may
522 be explained by the different approach of using consumption figures, i.e. food balance sheets instead
523 of actual food consumption surveys (3.4.3.1.).

524 Estimates obtained for adults with FACE and PRIMo 4 are approximately 2-3 times higher compared to
525 estimates obtained with GECDE for the general population. This is mainly due to the difference in
526 residue concentrations used (mean + 2 SD, mean vs median) and a different use of the consumption
527 data. Although the above-mentioned models are based on the same European food consumption data
528 sets in these estimations, these data are used in different ways. Specifically, both FACE and PRIMo 4
529 models use consumption data of dairy food that was converted to the RPC (RAC, milk in this case),
530 while GECDE considered consumption of liquid milk only. Additional calculations were carried out with
531 GECDE demonstrating that, when input values for GECDE are better aligned with the EFSA models (i.e.
532 using milk equivalence instead of cheese and butter or using mean+2SD instead of the median) FACE
533 and PRIMo 4, the obtained results are more comparable (see Table 10).

534 Considering that the conversion into raw primary commodities assumes no loss of the chemical during
535 the preparation of the processed food, the use of FACE and PRIMo 4 might overestimate the exposure.
536 For example, exposure to lipophilic compounds in cream might be adequately assessed whereas
537 exposure to a water-soluble compound in the same food will likely be overestimated.

538

539 **Table 10: Indicative comparisons of TMDI, FACE, PRIMo 4 and GECDE for bovine milk**

Hrs	TMDI	FACE ¹	FACE ²	PRIMo 4 ¹	PRIMo 4 ²	GECDE					
						Median conc	Mean+2SD conc	Mean+2SD conc (cheese, butter adjusted)	Median conc (cheese, butter adjusted)	Median conc (cheese, butter adjusted), mean consumption	Mean+2SD conc (cheese, butter adjusted), mean consumption
24	n.d.	0.0233	0.0472	0.0145	0.0405	0.017	0.027	0.064	0.040	0.012	0.020
36	n.d.	0.1865	0.2168	0.0581	0.1621	0.068	0.125	0.294	0.160	0.050	0.091
48	0.52	0.0729	0.1474	0.0694	0.1937	0.062	0.085	0.200	0.146	0.046	0.062
60	0.49	0.0826	0.1670	0.0791	0.2207	0.074	0.096	0.226	0.173	0.054	0.070
72	0.47	0.0972	0.1965	0.0807	0.2252	0.083	0.113	0.266	0.195	0.061	0.082
84	0.35	0.0761	0.1539	0.0727	0.2027	0.079	0.089	0.209	0.186	0.058	0.065
96	0.26	0.0745	0.1506	0.0614	0.1711	0.064	0.087	0.204	0.151	0.047	0.063
120	0.18	0.0518	0.1048	0.0452	0.1261	0.051	0.060	0.142	0.120	0.037	0.044
144	0.17	0.0470	0.0950	0.0404	0.1126	0.043	0.055	0.129	0.102	0.032	0.040
168	0.12	0.0373	0.0753	0.0307	0.0856	0.032	0.043	0.102	0.075	0.023	0.032
192	0.09	0.0211	0.0426	0.0210	0.0585	0.023	0.025	0.058	0.053	0.017	0.018
216	0.06	0.0178	0.0360	0.0145	0.0405	0.015	0.021	0.049	0.035	0.011	0.015

540 1 Adult maximum mean; 2 Adult maximum HRP

541 **4.2.2. Chicken (poultry) meat and offal and eggs**

542 **Meat and offal**

543 The outcome of the chronic exposure estimates for chicken meat and offal with the five models are summarised in Table 11.

544 **Table 11: Chronic exposure estimates for chicken (poultry) meat and offal expressed as µg/kg bw per day**

Day	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
1	8.44	2.12	2.58	2.33	1.44	1.02	0.74	0.70	1.60	2.31	2.03	1.19	0.86	0.57	0.51	2.00	0.34 (0.605/n)
2	6.76	1.72	2.06	1.88	1.18	0.80	0.60	0.57	1.24	1.80	1.58	0.92	0.67	0.44	0.39	1.60	0.26 (0.469/n)
4	4.37	1.31	1.56	1.40	0.88	0.56	0.45	0.43	0.87	1.26	1.11	0.64	0.47	0.30	0.28	1.10	0.18 (0.329/n)
7	2.35	0.69	0.83	0.75	0.47	0.33	0.24	0.23	0.49	0.71	0.62	0.35	0.26	0.17	0.16	0.60	0.10 (0.422/n)
10	1.30	0.51	0.61	0.54	0.35	0.22	0.18	0.17	0.28	0.40	0.35	0.20	0.14	0.10	0.09	0.30	0.06 (0.400/n)

545 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed, for comparison
546 with the other models, the EU-Cluster are given, but the values normally used by JMPR are mentioned in brackets (n: For these days no data on eggs were available.);
547 green-red = lowest-highest value in a row; in bold: highest value in a column
548

549 From the calculations it can be seen that, as for bovine meat and offal, the highest values result from the TMDI. This approach uses the highest residue
550 values (upper 95/95 tolerance limit), as can be seen in section 4.2.1.1, the upper 95/95 tolerance limit is up to 1.4-fold times higher than the mean + 2 SD
551 (used by FACE), up to 1.9-fold higher than the mean (as used in PRIMo 4) and up to 2.2-fold the median (used by GECDE).

552 In addition, consumption data used in the FACE and PRIMo 4 are lower than for the TMDI, at least for adults.

553 Furthermore, TMDI is adding the whole portion for all tissues while FACE and PRIMo 4 add the food commodities at an individual level, which means, that a
 554 person may eat a considerable amount of meat but not necessarily eat liver (or the other way round).

555 Again, the really low exposure levels for IEDI may be explained by the different approach to deriving consumption input data, using import, export and
 556 production data instead of consumption surveys (3.4.3.2.).

557 **Eggs**

558 The outcome of the chronic exposure estimates for eggs with the five models is summarised in Table 12.

559 **Table 12: Chronic exposure estimates for chicken eggs expressed as µg/kg bw per day**

Day	TMDI ¹	FACE ²							PRIMo 4							GECDE ¹	IEDI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old			
5	1.80	2.30	2.62	2.81	1.80	0.99	0.86	1.09	1.53	2.00	2.06	1.26	0.75	0.63	0.68	1.10	0.26
6	1.70	2.54	2.89	3.09	1.99	1.09	0.95	1.20	1.90	2.48	2.54	1.56	0.93	0.78	0.85	1.30	0.32
7	2.40	2.98	3.39	3.63	2.33	1.28	1.11	1.41	2.10	2.74	2.82	1.73	1.03	0.86	0.94	1.40	0.35
8	1.20	2.35	2.67	2.86	1.84	1.01	0.88	1.11	2.02	2.63	2.70	1.66	0.99	0.82	0.90	1.30	0.34
9	1.60	2.65	3.02	3.23	2.08	1.14	0.99	1.25	1.99	2.60	2.68	1.64	0.98	0.82	0.89	1.40	0.33
10	1.40	2.62	2.98	3.19	2.05	1.12	0.98	1.23	2.17	2.83	2.91	1.79	1.06	0.89	0.97	1.40	0.36
11	1.80	3.26	3.71	3.97	2.55	1.40	1.22	1.54	2.59	3.38	3.47	2.13	1.27	1.06	1.15	1.70	0.43
12	1.80	3.39	3.85	4.13	2.65	1.45	1.27	1.60	2.86	3.74	3.84	2.35	1.40	1.17	1.28	1.90	0.48
13	1.90	3.58	4.07	4.36	2.80	1.53	1.34	1.69	2.97	3.87	3.98	2.44	1.45	1.21	1.32	2.00	0.49
14	2.10	3.76	4.28	4.58	2.94	1.61	1.41	1.77	3.02	3.95	4.06	2.49	1.48	1.24	1.35	2.00	0.50
15	1.90	3.31	3.76	4.03	2.59	1.42	1.24	1.56	2.68	3.50	3.60	2.21	1.31	1.10	1.19	1.90	0.45
16	2.30	3.14	3.58	3.83	2.46	1.35	1.18	1.48	2.27	2.96	3.04	1.87	1.11	0.93	1.01	1.60	0.38
17	2.00	2.62	2.99	3.20	2.05	1.12	0.98	1.24	1.84	2.40	2.46	1.51	0.90	0.75	0.82	1.30	0.31
18	1.80	2.34	2.66	2.85	1.83	1.00	0.88	1.10	1.41	1.84	1.90	1.16	0.69	0.58	0.63	1.10	0.24

560 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed;
 561 green-red = lowest-highest value in a row; in bold: highest value in a column
 562

563 For eggs (similarly as for milk) the TMDI did not result in the highest dietary exposure value expressed on a µg/kg bw base. The highest dietary exposure
 564 values were derived for children up to an age of 10 years, calculated with the FACE model. For exposure estimates calculated with PRIMo 4 model, the age
 565 class for "other children" resulted in the highest dietary exposure value, directly followed by toddlers.

566 For adults, elderly and very elderly the consumption figures do not differ significantly but, on a bodyweight basis, children consumed much more eggs per kg
 567 bw than adults, and the consumption was also much higher compared with the value used in TMDI (which uses a standard assumption of 1.66 g egg per kg
 568 bw for a 60 kg adult).

569 With a look at the really low exposure levels for IEDI these cannot be explained by different residue input values only (especially in comparison to GECDE),
 570 but may be explained by the different approach to deriving consumption input data, using import, export and production data instead of real consumption
 571 surveys (3.4.3.1.).

572 4.2.3. Fish

573 The outcome of the chronic exposure estimates for fish with the five models is summarised in Table 13

574 *Table 13: Chronic exposure estimates for fish expressed as µg/kg bw per day*

Day	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
1	2.63	0.87	2.35	1.63	1.16	0.97	0.90	0.68	0.88	1.85	1.76	1.28	1.08	0.86	0.64	1.25	0.206 (0.352)
7	0.42	0.16	0.42	0.29	0.21	0.17	0.16	0.12	0.15	0.31	0.29	0.21	0.18	0.14	0.11	0.21	0.032 (0.055)
14	0.05	0.02	0.06	0.04	0.03	0.02	0.02	0.02	0.02	0.04	0.04	0.03	0.02	0.02	0.01	0.03	0.004 (0.007)

575 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed, for comparison
 576 with the other models, the EU-Cluster are given, but the values normally used by JMPR are mentioned in brackets;
 577 green-red = lowest-highest value in a row; in bold: highest value in a column

578

579 TMDI leads to the highest exposure estimate for fish. It seems that the differences can be explained by the different residue input values, which are in case
 580 of TMDI up to 1.8-fold higher than for the other models (see also Table 6).

581 Again, the really low exposure levels for IEDI in comparison to the other models, may be explained by the different approach to deriving consumption input
 582 data, using import, export and production data instead of real consumption surveys (3.4.3.1.).

583 **4.2.4. Honey**

584 The outcome of the chronic exposure estimates for honey with the five models is summarised in Table 14.

585 *Table 14: Chronic exposure estimates for honey expressed as µg/kg bw per day*

TG1 (B)	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
Day 7	21.71	0.09	1.15	1.45	0.87	0.75	0.97	0.93	0.06	0.71	1.14	0.63	0.49	0.67	0.66	1.26	0.05
Day 16	118.20	0.08	0.96	1.21	0.72	0.62	0.81	0.78	0.04	0.53	0.85	0.47	0.37	0.50	0.49	0.93	0.04
TG1 (D)	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
Day 7	21.19	0.11	1.39	1.75	1.04	0.90	1.17	1.12	0.06	0.76	1.22	0.67	0.53	0.72	0.70	1.43	0.054
Day 16	19.44	0.10	1.28	1.61	0.96	0.83	1.07	1.03	0.05	0.64	1.03	0.57	0.45	0.61	0.60	0.91	0.046
TG2 (B)	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
Day 7	4.21	0.10	1.22	1.54	0.91	0.79	1.03	0.99	0.07	0.87	1.40	0.77	0.61	0.83	0.80	1.34	0.062
Day 16	2.00	0.09	1.09	1.37	0.82	0.71	0.92	0.88	0.07	0.84	1.34	0.74	0.58	0.80	0.78	1.29	0.060

TG2 (D)	TMDI ¹	FACE ²						PRIMo 4 ²						GECDE ¹	IEDI ³		
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old			
Day 7	9.55	0.08	1.08	1.36	0.81	0.70	0.91	0.87	0.05	0.63	1.01	0.56	0.44	0.60	0.58	0.91	0.045
Day 16	11.52	0.08	0.96	1.21	0.72	0.63	0.81	0.78	0.05	0.55	0.89	0.49	0.39	0.53	0.51	0.75	0.039

586 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed;
587 green-red = lowest-highest value in a row; in bold: highest value in a column

588

589 The impact of different residue input values becomes apparent in this example. The residue concentrations of the hives are very different, resulting in huge
590 tolerance limits (used by TMDI), which are 2- 142-fold above the values used by FACE, 4 to 349-fold higher than those used in PRIMo 4 and between 4.2
591 and 346-fold above the values used by GECDE/IEDI.

592 However, as for the other food commodities, the really low exposure levels for IEDI may be explained by the different approach to deriving consumption
593 input data, using import, export and production data instead of real consumption surveys (3.4.3.1.).

594 4.2.5. Combined exposure for a substance used in all food producing species

595 As discussed above, there are differences in the data inputs used in the different exposure models. Specifically, different residue input data are taken (upper
596 tolerance limit, mean + 2 SD, mean or median), and different consumption figures are used (see 3.3.). Also, the approaches for combined exposure from
597 multiple species are slightly different.

598 The data sets for cattle (mammals), chicken (poultry), fish and honey were combined, and exposure estimates were calculated for the purpose of evaluating
599 the impact of the different procedures.

600 For the combined (chronic) exposure it would seem to make sense that the same time points will be used in each model. For this exercise, it was proposed
601 to calculate at least one scenario using residue values from day 7 for cattle tissues and day 1 for chicken and day 1 for fish (based on the earliest time
602 points/tentatively highest mean values). For honey and milk, it was suggested to take the time point of the highest mean values (i.e. milk 72 h and honey
603 day 7, i.e. the values for TG2 (B)). For eggs, it was suggested to use residue data from day 7 (highest UTL).

604

605 **Table 15 Combined chronic exposure estimates for cattle (incl. milk), chicken (incl. eggs), fish and honey expressed as µg/kg bw per day**

TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesce nts ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesce nts ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
17.26	5.13	6.30	5.82	3.55	2.44	2.42	2.35	3.73	5.06	4.82	2.98	1.98	1.82	1.56	3.1	1.05

606 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed;

607 green-red = lowest-highest value in a row;

608 * Includes adjustment for inclusion of cheese and butter in milk description (see 4.1.2.4)

609

610 It can be seen that in this example TMDI leads to the highest chronic dietary exposure estimate for all population subgroups. The reason might be that TMDI
611 uses the standard food basket with consumption figure of 0.3 kg muscle (highest of chicken, bovine or fish), 0.1 kg of liver (highest of chicken, bovine), fat
612 (highest of 0.09 kg skin+fat from chicken or 0.05 kg for bovine), kidney (highest of 0.01 from chicken or 0.05 kg for bovine), milk and eggs for a 60 kg
613 person. It is calculated for each day as: TMDI = Σ consumption figure x 95/95 upper tolerance limit (for milk, eggs and honey pointwise UTL)

614 In contrast, for the GECDE dietary exposure estimate including all tissues, the main contributor to dietary exposure was eggs – the exposure estimate
615 included the contribution from eggs for a 97.5th percentile consumer and contributions from all other matrices at the maximum population mean. The
616 contribution from eggs accounted for 90% of the total GECDE. 'Mean dietary exposure' for GECDE has been calculated using the highest population mean
617 consumption values for each food type.

618 For FACE and PRIMo 4 individual consumption figures were used, which means, for example, that a person may eat a considerable amount of meat not
619 necessarily eat liver (or the other way around). Additionally, for FACE the residue input value is the mean+2SD and for PRIMo 4 it is equal to the mean,
620 which are typically lower than the 95/95 upper tolerance limit used by TMDI.

621 IEDI uses import, export and production data instead of real consumption surveys. Therefore, a direct comparison with the other models is difficult.

622 **4.3. Acute Exposure**

623 No specific calculation is done to estimate acute exposure in the TMDI. To derive exposure estimates, TMDI uses the consumption data from the SFB and the
624 upper 95/95 tolerance of the residue depletion data (3.4.1). TMDI is assumed to be conservative enough to also (partly) cover acute exposure (the term ADI
625 also includes acute endpoints such as the pharmacological ADI). The values are in principle the same as for the chronic exposure (i.e. referring to the sum of
626 tissues/exposures and not a single tissue).

627 FACE uses the individual consumption figures of the RPC Consumption Database based on the consumption of a food commodity within a single day and the
628 mean +2SD from the residue depletion data (3.4.2.1.).

629 In PRIMo revision 4, acute exposure is calculated by combining individual food consumption data within a single day from the RPC consumption database
630 with the high residue concentration (HR) of the residue data (3.4.3.2.). The HR corresponds to the highest measured residue concentration in each
631 commodity.

632 For GEADE, upper 95/95 residue and highest 97.5th percentile single day consumption (large portion database) are used. Large portions used included
633 values from Bulgaria (muscle), Bulgaria and Thailand (liver), France and Greece (kidney) and China and Poland (fat). Calculations are carried out for each
634 tissue type and the highest individual exposure value is used as GEADE – assumed that a person will not consume large portion with high residue of more
635 than one tissue type on the same day. Consumption is expressed in g/kg bw. (3.4.1.2.).

636 The IESTI-Model is based on consumption data/models from various Codex Member Countries. In the spreadsheet, only the single diet/model resulting in the
637 highest exposure is calculated. This may either be a specific population group (e.g. Children, 1-6 yrs, CN) or a supranational model (EFSA PRIMo.rev.3, FR
638 adult)(3.4.3.1.).

639 4.3.1. Bovine (mammals) meat and offal and milk

640 Meat and offal

641 The outcome of the acute dietary exposure estimates for bovine meat and offal with the five models are summarised in Table 16.

642 Table 16: Acute exposure estimates for bovine meat and offal expressed as µg/kg bw

Day	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ¹		IEST I ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP*	CH	**
7	2.58	1.07	1.15	1.65	1.10	0.87	0.63	0.65	1.07	1.30	1.68	1.34	1.55	1.02	0.76	6.60	7.30	1.86
14	0.76	0.26	0.28	0.40	0.27	0.26	0.15	0.16	0.24	0.40	0.52	0.33	0.48	0.31	0.23	1.90	2.10	0.57
21	0.26	0.27	0.21	0.41	0.22	0.30	0.14	0.13	0.40	0.71	0.92	0.52	0.85	0.56	0.41	0.62	0.68	1.051
28	0.10	0.05	0.05	0.07	0.05	0.05	0.03	0.03	0.05	0.09	0.11	0.06	0.11	0.07	0.05	0.22	0.24	0.127

643 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; to note: PRIMo 4 normally distinguishes between cattle and
644 other mammalian species, however for better comparison with FACE, the values for mammalian species were used here; 3) average bodyweights are assumed;
645 green-red = lowest-highest value in a row;
646 * consumption data of Bulgaria and Thailand (liver); ** consumption data of South Africa, China and Primo.rev.3-FR
647 GP=general population, CH=children

648

649 The models using world-wide data (GEADE, IESTI) lead to higher exposure estimates compared to the European models. One reason for this might be that
650 consumption figures from third countries are at least for some commodities higher than those for European countries. E.g. for GEADE the highest exposure
651 results were associated with consumption of liver based on data from Thailand. It needs to be discussed in how far those data are representative for food
652 consumption habits in Europe and hence if they should be considered or not. A comparison of acute consumption figures can be found in chapter 5.2.

653

654 **Milk**

655 The outcome of the acute dietary exposure estimates for milk with the five models are summarised in Table 17.

656 **Table 17: Acute exposure estimates for milk expressed as µg/kg bw**

Hrs	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ¹		IESTI ₃
		Infants < 12 months old	Toddler s ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesc ents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddler s ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesc ents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP*	CH*	***
24	n.d.	0.19	0.18	0.26	0.09	0.05	0.05	0.05	0.12	0.09	0.28	0.13	0.13	0.03	0.03	ND	ND	0.112
36	n.d.	0.89	0.84	1.19	0.42	0.24	0.21	0.23	0.49	0.37	1.12	0.53	0.50	0.11	0.13	ND	ND	n.c.
48	0.52	0.61	0.57	0.81	0.29	0.16	0.15	0.15	0.59	0.45	1.33	0.63	0.60	0.13	0.16	1.30	2.3	0.534
60	0.49	0.69	0.65	0.92	0.32	0.18	0.17	0.17	0.67	0.51	1.52	0.72	0.69	0.15	0.18	1.30	2.2	n.c.
72	0.47	0.81	0.76	1.08	0.38	0.21	0.19	0.20	0.69	0.52	1.55	0.74	0.70	0.15	0.18	1.20	2.1	0.621
84	0.35	0.63	0.59	0.84	0.30	0.17	0.15	0.16	0.62	0.47	1.40	0.66	0.63	0.14	0.16	0.89	1.5	n.c.
96	0.26	0.62	0.58	0.83	0.29	0.16	0.15	0.16	0.52	0.40	1.18	0.56	0.53	0.11	0.14	0.66	1.2	0.472
120	0.18	0.43	0.40	0.57	0.20	0.11	0.10	0.11	0.38	0.29	0.87	0.41	0.39	0.08	0.10	0.45	0.79	0.348
144	0.17	0.39	0.37	0.52	0.18	0.10	0.09	0.10	0.34	0.26	0.78	0.37	0.35	0.08	0.09	0.43	0.74	0.311
168	0.12	0.31	0.29	0.41	0.15	0.08	0.07	0.08	0.26	0.20	0.59	0.28	0.27	0.06	0.07	0.31	0.54	0.236
192	0.09	0.17	0.16	0.23	0.08	0.05	0.04	0.04	0.18	0.14	0.40	0.19	0.18	0.04	0.05	0.22	0.39	0.161
216	0.06	0.15	0.14	0.20	0.07	0.04	0.04	0.04	0.12	0.09	0.28	0.13	0.13	0.03	0.03	0.16	0.28	0.112

657 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; to note: PRIMo 4 normally distinguishes between cattle and
 658 other mammalian species, however for better comparison with FACE, the values for mammalian species were used here; 3) average bodyweights are assumed;
 659 green-red = lowest-highest value in a row;
 660 * consumption data of Finland; ** consumption data of Canada, *** consumption data of Primo.rev.3-UK
 661 GP=general population, CH=children
 662

663 Also, for milk, the international models result in higher exposure estimates, at least for the adult population but also for children with the GEADE. This is
 664 interesting as only GEADE for children uses consumption figures from a third country (here Canada). The comparison of the residue input value (upper 95/95
 665 tolerance limit vs mean+2SD, upper 95/95 tolerance limit vs mean) shows that the value used by TMDI and GEADE is up to 4.6-fold higher than the value
 666 used by FACE and up to 2-fold higher than that used by PRIMo 4. As TMDI and GEADE use the same residue input value, the difference in the exposure
 667 estimate might be mainly in the consumption figures used.

668 With a look at the European population, it becomes evident, that regarding residues in milk, children are of special importance. Infants, toddlers and other
 669 children exposure calculated with FACE and PRIMo 4 models are higher than the values estimated with the TMDI (based on a body weight base).

670 4.3.2. Chicken (poultry) meat and offal and eggs

671 Meat and offal

672 The outcome of the acute dietary exposure estimates for meat and offal from chicken with the five models are summarised in Table 18.

673 Table 18: Acute exposure estimates for meat and offal from chicken (poultry) expressed as µg/kg bw

Day	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ¹		IESTI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP	CH	*	
1	8.44	3.71	3.47	10.91	5.86	9.62	2.36	1.65	4.05	5.18	11.31	7.02	9.68	4.71	4.69	16.30	12.70	12.75
2	6.76	3.03	2.83	8.06	4.32	7.10	1.74	1.34	3.06	3.55	7.75	4.81	6.63	3.22	3.21	13.00	10.10	8.73
4	4.37	2.30	2.15	5.01	2.69	4.42	1.08	1.02	2.23	2.47	4.87	3.02	4.17	2.03	2.02	8.40	6.50	5.49
7	2.35	1.22	1.14	3.45	1.85	3.04	0.75	0.54	1.28	1.64	3.58	2.22	3.06	1.49	1.48	4.40	3.40	4.03
10	1.30	0.90	0.84	1.92	1.03	1.69	0.42	0.40	1.01	1.12	2.01	1.25	1.72	0.84	0.83	2.40	1.90	2.26

674 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; 3) average bodyweights are assumed;
 675 green-red = lowest-highest value in a row;
 676 * consumption data of China, Canada and Primo-UK
 677 GP=general population, CH=children
 678

679 The comparison of the international and European estimates led to similar conclusions as for bovine (mammalian) meat and offal. However, unlike bovine
680 (mammalian) meat and offal, the highest exposure estimate is obtained for GEADE European data (Germany and Poland (poultry offal)). The differences
681 might be explained as GEADE uses only summary statistics whereas FACE and PRIMo 4 use individual consumption data. Further on, the residue input value
682 used by GEADE is up to 1.4- and 1.5-fold higher than the values used by FACE and PRIMo 4, respectively.

683 Comparing the European models for adults similar results are obtained, while the "other children" age class has slightly higher exposure estimates and the
684 other sub populations lower exposure estimates.

685 **Eggs**

686 The outcome of the acute dietary exposure estimates for eggs with the five models are summarised in Table 19.

687 **Table 19: Acute exposure estimates for eggs expressed as µg/kg bw**

Day	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ¹		IESTI ₃
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP	CH	*
5	1.80	5.06	4.74	4.30	2.55	1.82	1.87	1.63	6.57	7.38	6.64	3.04	3.37	2.60	2.98	7.80	13.00	7.08
6	1.70	5.57	5.21	4.74	2.81	2.01	2.06	1.80	7.69	8.64	7.78	3.56	3.94	3.04	3.49	7.60	12.60	8.29
7	2.40	6.54	6.12	5.56	3.30	2.36	2.42	2.11	8.80	9.88	8.89	4.07	4.51	3.48	3.99	10.40	17.30	9.47
8	1.20	5.16	4.83	4.39	2.60	1.86	1.91	1.66	8.11	9.11	8.20	3.75	4.16	3.21	3.67	5.40	9.00	8.73
9	1.60	5.82	5.45	4.95	2.94	2.10	2.15	1.88	8.15	9.16	8.24	3.77	4.18	3.23	3.69	7.10	11.70	8.78
10	1.40	5.74	5.38	4.88	2.90	2.07	2.12	1.85	8.41	9.46	8.51	3.89	4.31	3.33	3.81	6.20	10.30	9.06
11	1.80	7.16	6.70	6.08	3.61	2.58	2.65	2.31	10.37	11.65	10.48	4.79	5.31	4.10	4.70	8.10	13.30	11.17
12	1.80	7.43	6.96	6.32	3.75	2.68	2.75	2.40	11.04	12.41	11.17	5.11	5.66	4.37	5.00	8.00	13.20	11.89
13	1.90	7.86	7.36	6.68	3.96	2.84	2.91	2.53	12.36	13.88	12.49	5.71	6.33	4.89	5.60	8.50	14.10	13.31
14	2.10	8.25	7.73	7.02	4.16	2.98	3.05	2.66	12.28	13.79	12.41	5.68	6.29	4.86	5.56	9.10	15.10	13.22
15	1.90	7.26	6.79	6.17	3.66	2.62	2.68	2.34	10.55	11.86	10.67	4.88	5.41	4.17	4.78	8.10	13.40	11.37
16	2.30	6.91	6.46	5.87	3.48	2.49	2.55	2.23	9.84	11.06	9.95	4.55	5.04	3.89	4.46	10.20	16.90	10.60
17	2.00	5.76	5.39	4.90	2.90	2.08	2.13	1.86	7.74	8.70	7.82	3.58	3.97	3.06	3.51	8.60	14.20	8.34
18	1.80	5.14	4.81	4.37	2.59	1.85	1.90	1.66	7.34	8.25	7.42	3.39	3.76	2.90	3.33	8.00	13.30	7.91

688 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; 3) average bodyweights are assumed,;

689 green-red = lowest-highest value in a row;

690 * consumption data of UK

691 GP=general population, CH=children

692

693 Again, differences in the exposure estimates might be explained mainly by different consumption figures. For GEADE, large portion data for egg consumption
694 are from France (adults) and China (children), whereas IESTI uses data from UK. Therefore, differences in comparison to FACE and PRIMo 4 cannot be
695 explained by different consumption figures only. But again, the residue input value is up to 1.2-fold higher compared to the two EFSA models with both
696 differences together leading to the different exposure estimates.

697 Despite the fact that the residue value for TMDI is higher than for FACE, it results in similar exposure values for adult and older population subgroups. For
698 PRIMo 4, the exposure estimates are higher than those calculated with the TMDI also for the adults, elderly and very elderly age classes (up to 3-fold),

699 despite the lower input occurrence values used for the European model. However, it can be seen that exposure estimates (based on a kg body weight base)
 700 for infants, toddlers and children is 2.3-4.3 fold higher with FACE than for TMDI.

701 4.3.3. Fish

702 The outcome of the acute dietary exposure estimates for fish with the five models are summarised in Table 20.

703 **Table 20: Acute exposure estimates for fish expressed as µg/kg bw**

Day	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ¹		IESTI ³
	Infants < 12 months old	Toddler s ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesc ents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddler s ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesc ents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP*	CH**	**	
1	2.63	3.33	4.85	4.20	3.88	2.77	2.13	1.94	4.82	4.99	5.05	3.19	3.11	2.95	2.14	14.20	16.00	14.47
7	0.42	0.60	0.87	0.75	0.69	0.50	0.38	0.35	0.81	0.84	0.85	0.54	0.52	0.50	0.36	2.30	2.60	2.02
14	0.05	0.08	0.12	0.11	0.10	0.07	0.05	0.05	0.11	0.11	0.11	0.07	0.07	0.06	0.05	0.29	0.32	0.33

704 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; 3) average bodyweights are assumed;

705 green-red = lowest-highest value in a row;

706 *consumption data of Slovakia; **consumption data of Canada

707 GP=general population, CH=children

708

709 There are really big differences between the international and the European models for the exposure estimates for fish. These differences cannot be
 710 explained by the different input values, which differ only up to 1-2 fold. The consumption figures for IESTI and GEADE (children) are from Canada, which
 711 might explain the differences. However, the data for GEADE (general population) are from a European country, therefore other differences (e.g. summarised
 712 statistic instead of individual consumption figures) might be the reason for the different exposure estimate.

713 **4.3.4. Honey**

714 The outcome of the acute dietary exposure estimates for honey with the five models are summarised in Table 21.

715 *Table 21: Acute exposure estimates for honey expressed as µg/kg bw*

TG1 (B)	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ₁		TESTI ₃
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP	CH	*	
Day 7	21.71	2.49	4.27	5.27	3.38	3.51	2.46	2.41	2.09	4.04	4.10	2.90	3.87	3.06	1.94	n.c.	n.c.	8.45
Day 16	118.20	2.07	3.56	4.40	2.82	2.93	2.06	2.01	1.70	3.30	3.35	2.37	3.16	2.50	1.58	n.c.	n.c.	6.9
TG1 (D)	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ₁		TESTI ₃
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP	CH	*	
Day 7	21.19	3.00	5.14	6.35	4.07	4.23	2.97	2.90	2.57	4.98	5.05	3.58	4.77	3.77	2.39	n.c.	n.c.	10.41
Day 16	19.44	2.75	4.72	5.83	3.74	3.89	2.73	2.67	2.42	4.69	4.75	3.37	4.49	3.55	2.25	n.c.	n.c.	9.8
TG2 (B)	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ₁		TESTI ₃
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP	CH	*	
Day 7	4.21	2.63	4.51	5.57	3.57	3.71	2.60	2.55	2.33	4.50	4.57	3.24	4.32	3.41	2.16	n.c.	n.c.	9.42
Day 16	2.00	2.35	4.03	4.98	3.20	3.32	2.33	2.28	2.40	4.65	4.71	3.34	4.45	3.52	2.23	n.c.	n.c.	9.72

TG2 (D)	TMDI ¹	FACE ²							PRIMo 4 ²							GEADE ₁		IESTI ₃
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	GP	CH	*
Day 7	9.55	2.33	4.00	4.94	3.17	3.29	2.31	2.26	2.12	4.09	4.15	2.94	3.92	3.10	1.97	n.c.	n.c.	8.56
Day 16	11.52	2.08	3.56	4.40	2.82	2.93	2.06	2.01	1.76	3.40	3.45	2.44	3.26	2.57	1.63	n.c.	n.c.	7.11

716 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; 3) average bodyweights are assumed;

717 green-red = lowest-highest value in a row;

718 *consumption data from China

719 GP=general population, CH=children

720

721 It should be noted that (as explained in 4.2.4) the residue concentrations of the different hives are very diverse, resulting in huge tolerance limits and TMDIs
722 which are 2- to 142-fold above the value used by FACE, 2- to 187-fold those used by PRIMo 4 and up to 4.2-187-fold above the value used by IESTI.
723 Because of these differences JECFA Experts decided not to use these data for an exposure estimate. However, as these were data from a real residue
724 depletion study the exposure estimates was calculated for the remaining models.

725 Interestingly, although TMDI uses higher residue input values than the other models it does not result in the highest estimates at every time point, leading
726 to the assumption that the consumption figure used by TMDI is lower than for the other models.

727 5. Exercise to compare consumption figures of different models, using a default residue value 728 of 1 mg/kg

729 After comparison of exposure estimates as used by EFSA, EMA, JECFA and JMPR by using real residue data (see Section 4), it becomes evident that
730 differences cannot only be explained by different residue input data. Therefore, the influence of the different consumption figures/assumptions used in the
731 models were evaluated. For the JECFA and JMPR models, for comparison reasons, European data were used where possible. However, in both cases this is
732 only possible for the chronic estimate.

733 Therefore, calculations were conducted using a unique default residue value of 1 mg/kg (1000 µg/kg) and consumption figures as used normally in the
734 different models.

735 **5.1. Chronic exposure**

736 The outcome of the chronic exposure models is summarised in tables 22-26.

737 **Table 22: Chronic exposure estimates for bovine (mammalian) meat and offal and milk expressed as µg/kg bw per day**

Tissue

	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
Liver	1.67	0.48	0.55	0.41	0.21	0.39	0.24	0.26	0.67	0.72	0.68	0.36	0.58	0.52	0.30	1.30	0.25
Kidney	0.83	0.00	0.09	0.68	0.58	0.92	0.48	0.29	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.74	0.25
Fat	0.83	0.76	0.92	0.72	1.00	0.59	0.40	0.37	0.95	1.07	1.02	1.19	0.71	0.45	0.40	0.26	0.31
Muscle	5.00	4.64	7.66	8.56	6.83	4.75	3.58	3.44	5.48	8.76	8.87	7.70	5.33	3.97	4.01	4.23	2.51
Tissue (total)	8.33	5.63	7.99	8.63	6.96	5.42	3.65	3.52	6.65	8.76	9.28	8.16	6.16	4.11	4.17	4.29	2.86

*IEDI gives only one value for "offal", for illustrational reasons used for liver and kidney

Milk

	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
	25.00	124.11	122.34	161.01	58.70	32.74	28.96	32.68	136.62	128.68	163.21	65.32	45.04	34.33	39.32	44	7.81

Combination of cattle (mammalian) tissue and milk

	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		

33.00	124.11	126.38	162.29	61.62	34.02	31.17	33.97	136.62	136.19	164.96	70.01	46.49	35.62	40.62	46	10.18
-------	--------	--------	--------	-------	-------	-------	-------	--------	--------	--------	-------	-------	-------	-------	----	-------

738
739
740
741

1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; to note: PRIMo 4 normally distinguishes between cattle and other mammalian species, however for better comparison with FACE, the values for mammalian species were used here; 3) average bodyweights are assumed green-red = lowest-highest value in a row;

742

Table 23 Chronic exposure estimates for chicken (poultry) meat and offal and eggs expressed as µg/kg bw per day

Tissue	TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ₁	IEDI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
Liver	1.67	0.00	0.19	0.26	0.05	0.29	0.04	0.12	0.00	0.35	0.42	0.09	0.44	0.34	0.12	1.54	0.02
Kidney	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00								-	0.02
Fat	1.50	0.00	0.15	0.21	0.04	0.03	0.02	0.02	0.00	0.33	0.37	0.06	0.05	0.08	0.02	0.02	0.01
Muscle	5.00	6.53	7.71	6.35	4.33	2.26	1.99	2.07	6.88	9.13	7.86	4.79	2.70	2.10	2.08	5.36	1.45
Tissue (total)	8.33	6.60	7.71	6.45	4.33	2.35	2.07	2.07	7.09	9.13	7.86	4.79	2.73	2.10	2.08	5.50	1.46

*IEDI gives only one value for "offal", for illustrational reasons used for liver and kidney;

Eggs

TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ₁	IEDI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
1.67	3.43	3.91	4.18	2.69	1.47	1.28	1.62	3.65	4.76	4.90	3.00	1.79	1.49	1.63	2.50	0.61

Combination of chicken (poultry) tissue and eggs

TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ₁	IEDI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months	Other children ≥ 36 months	Adolescents ≥ 10 years to	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months	Other children ≥ 36 months	Adolescents ≥ 10 years to	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		

		months old	to < 10 years old	< 18 years old					months old	to < 10 years old	< 18 years old						
10.00	8.34	9.94	8.57	5.04	3.17	3.03	2.86	9.01	11.86	10.07	6.01	3.63	3.04	2.86	6.30	2.01	

743 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed;
744 green-red = lowest-highest value in a row
745

746 **Table 24: Chronic exposure estimates for fish meat expressed as µg/kg bw per day**

TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
5.00	2.13	5.73	3.98	2.82	2.35	2.19	1.66	2.93	6.12	5.83	4.22	3.57	2.84	2.11	4.00	0.72

*highest value of Freshwater fish (e.g. tilapia), Diadromous fish (e.g. salmon, trout) or Marine fish used

747 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed;
748 green-red = lowest-highest value in a row
749

750 **Table 25: Chronic exposure estimates for honey expressed as µg/kg bw per day**

TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
0.33	0.03	0.39	0.49	0.29	0.25	0.32	0.31	0.04	0.52	0.83	0.46	0.36	0.49	0.48	0.90	0.037

751 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed;
752 green-red = lowest-highest value in a row
753

754 **Table 26: Combined chronic exposure estimates for cattle (incl. milk), chicken (incl. eggs), fish and honey expressed as µg/kg bw per day**

TMDI ¹	FACE ²							PRIMo 4 ²							GECDE ¹	IEDI ³
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesce nts ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesce nts ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
40.33	129.18	128.41	164.63	63.52	35.50	32.22	34.98	138.78	138.47	168.39	71.71	49.63	37.26	42.60	59	12.25

755 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) HRP calculated at individual body weights; 3) average bodyweights are assumed;
756 green-red = lowest-highest value in a row
757

758 For cattle tissue and milk, the highest exposure is obtained for “other children” when FACE and PRIMo 4 are used. Regarding poultry tissue and eggs, the
759 highest exposure is obtained for general population with TMDI and for toddlers when FACE and PRIMo are used. For fish, the highest exposure is obtained
760 with TMDI and for “toddlers” with FACE and PRIMo. In case of honey the highest exposure is obtained with GECDE. For the combined exposure, the highest
761 exposure is obtained for “other children” when FACE and PRIMo are used

762 The calculations show that in case of chronic exposure assessment, the food basket used for TMDI seems to be the most conservative model and covers all
763 population subgroups for most foodstuffs, except eggs and milk in children (in comparison with FACE and PRIMo 4) and honey (in comparison with GECDE).

764 On a body weight base, the consumption figures for milk and eggs of children from the EFSA database are much higher than assumed by the TMDI. The
765 impact of this finding will be discussed in the following sections.

766 Concerning the models using real consumption figures, some differences might be explained by the fact that JECFA uses summary statistics, while EFSA uses
767 individual data. Furthermore, JECFA and JMPR use data from the whole world, whereas EFSA uses European data only. For the chronic estimates with the
768 JMPR model, differences by using the clusters containing European data or all clusters are given in the table, were applicable. However, even the clusters
769 containing European data sometimes contain also third country data.

770 In contrast to JECFA and EFSA, JMPR uses import, export and production data. As discussed in the example with real residue data, this approach leads to
771 very low exposure estimates, probably because of low consumption figures.

772 Despite FACE and PRIMo 4 using the exact same consumption data, a difference is observed between both models with PRIMo 4 resulting in slightly higher
773 estimates compared to FACE. This is due to the fact that the highest reliable percentile (HRP) of the exposure obtained with FACE is only derived up to the
774 95th percentile, whereas in PRIMo 4 HRP estimates are derived up to the 97.5th percentile.

775

776

777 **5.2. Acute exposure**

778 The consumption figures for acute exposure scenarios differ to the consumption figures used for chronic exposure estimates (5.1.). As described for the
 779 different models (3.4.1. -3.4.4.), normally acute exposure estimates are based on a high percentile consumed within one day.

780 **Table 27: Overall acute exposure estimates for bovine (mammalian) meat and offal and milk expressed as µg/kg bw**

Tissue																	
	TMDI¹	FACE²							PRIMo 4²							GEADE₁	IES³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
Liver	1.67	3.48	2.68	5.15	2.74	3.74	1.72	1.62	3.71	4.69	5.47	3.60	4.51	2.64	2.10	8.30	9.40
Kidney	0.83		4.54	8.47	4.76	5.64	4.35	3.83			4.76	1.72	2.09	1.59		12.90	9.40
Fat	0.83	2.39	2.38	1.87	1.52	1.05	0.97	1.00	2.39	2.60	1.96	1.78	1.34	0.97	1.01	4.80	2.03
Muscle	5.00	10.47	11.24	16.18	10.82	7.34	6.19	6.35	8.92	11.44	13.33	12.24	7.69	5.37	4.63	10.70	16.41
Tissue (total)	8.33	10.47	11.24	16.18	10.82	7.34	6.19	6.35	8.92	11.44	13.33	12.24	7.69	5.37	4.63	12.90	16.41

*IES³ gives only one value for "offal", for illustrational reasons used for liver and kidney only fat from EU-survey

Milk																	
	TMDI¹	FACE²							PRIMo 4²							GEADE₁	IES³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
	25.00	134.59	126.55	179.43	63.59	35.80	32.47	34.12	137.10	104.02	310.13	147.18	140.00	30.18	36.17	64	124.22

Combination of cattle (mammalian) tissue and milk																	
	TMDI¹	FACE²							PRIMo 4²							GEAST DE¹	IESDI³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months	Other children ≥ 36 months	Adolescents ≥ 10 years to	Adults ≥ 18 years to	Elderly ≥ 65 years to	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months	Other children ≥ 36 months	Adolescents ≥ 10 years to	Adults ≥ 18 years to	Elderly ≥ 65 years to	Very elderly ≥ 75 years old		
																	**

		months old	to < 10 years old	< 18 years old	< 65 years old	< 75 years old			months old	to < 10 years old	< 18 years old	< 65 years old	< 75 years old			
33.00	134.59	126.55	179.43	63.59	35.80	32.47	34.12	137.10	104.02	310.13	147.18	140.00	30.18	36.17	64	124.22

781 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; to note: PRIMo 4 normally distinguishes between cattle and
782 other mammalian species, however for better comparison with FACE, the values for mammalian species were used here; 3) average bodyweights are assumed;
783 green-red = lowest-highest value in a row
784

785 **Table 28 Overall acute exposure estimates for chicken (poultry) meat and offal and eggs expressed as µg/kg bw**

Tissue

	TMDI ₁	FACE ²							PRIMo 4 ²							GEAD E ¹	IESTI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
Liver	1.67	1.50	0.75	5.50	2.95	4.85	1.19	0.48	2.06	2.64	5.76	3.57	4.93	2.40	2.39	7.20	6.49
Kidney	0.17	0.00	0.00	0.00	0.00	2.30	0.00	0.00								7.20	6.49
Fat	1.50		0.75	0.88	0.91	0.66	0.25	0.34	0.24	0.84	1.12	0.91	0.78	0.47	0.41	2.30	2.90
Muscle	5.00	11.92	11.16	14.30	8.77	6.41	5.45	5.30	12.97	14.36	15.43	9.64	8.55	6.43	5.30	15.40	21.51
Tissue (total)	8.33	11.92	11.16	14.30	8.77	6.41	5.45	5.30	12.97	14.36	15.43	9.64	8.55	6.43	5.30	15.40	21.51

*IESTI gives only one value for "offal", for illustrational reasons used for liver and kidney survey from China and Canada

Eggs

	TMDI ¹	FACE ²							PRIMo 4 ²							GEAD E ¹	IESTI ³
		Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
	1.67	7.54	7.05	6.41	3.80	2.72	2.79	2.43	11.53	12.95	11.65	5.33	5.91	4.56	5.22	7.30	12.41

Combination of chicken (poultry) tissue and eggs

TMDI ¹	FACE ²	PRIMo 4 ²	GEAD E ¹	IESTI ³

	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old			
	10.00	11.92	11.16	14.30	8.77	6.41	5.45	5.30	12.97	14.36	15.43	9.64	8.55	6.43	5.30	15.40	21.51

786 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; 3) average bodyweights are assumed;
787 green-red = lowest-highest value in a row
788

789 **Table 29: Overall acute exposure estimates for fish meat expressed as µg/kg bw**

TMDI¹	FACE²							PRIMo 4²							GEADE₁	IEST_{I³}	
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old			
	5.00	8.11	11.82	10.23	9.45	6.76	5.20	4.72	11.03	11.41	11.57	7.29	7.12	6.76	4.90	27.80	31.26

*highest value of Freshwater fish (e.g. tilapia), Diadromous fish (e.g. salmon, trout) or Marine fish used survey from Canada

790 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; 3) average bodyweights are assumed;
791 green-red = lowest-highest value in a row
792

793 **Table 30: Overall acute exposure estimates for honey expressed as µg/kg bw**

TMDI¹	FACE²							PRIMo 4²							GEADE₁	IEST_{I³}	
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolescents ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old			
	0.33	0.83	1.43	1.76	1.13	1.18	0.82	0.81	0.90	1.74	1.76	1.25	1.67	1.32	0.83	5.50	3.64

*survey from China

794 1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; 3) average bodyweights are assumed;
795 green-red = lowest-highest value in a row
796

797

Table 31: Overall acute exposure estimates for cattle (incl. milk), chicken (incl. eggs), fish and honey expressed as µg/kg bw

TMDI ₁	FACE ²							PRIMo 4 ²							GEADE ₁	IESTI ₃
	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesce nts ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old	Infants < 12 months old	Toddlers ≥ 12 months to < 36 months old	Other children ≥ 36 months to < 10 years old	Adolesce nts ≥ 10 years to < 18 years old	Adults ≥ 18 years to < 65 years old	Elderly ≥ 65 years to < 75 years old	Very elderly ≥ 75 years old		
40.33	134.59	126.55	179.43	63.59	35.80	32.47	34.12	137.10	104.02	310.13	147.18	140.00	30.18	36.17	64	124.22

798
799
800

1) TMDI and GECDE calculated for a standard body weight of 60 kg/person; 2) calculated at individual body weights; 3) average bodyweights are assumed; green-red = lowest-highest value in a row

801 For cattle tissue and milk, the highest exposure is obtained for "other children" when FACE and PRIMo
802 are used. In case of poultry tissue and eggs, the highest exposure is obtained with IESTI and for
803 "other children" when FACE and PRIMo are used. For fish, the highest exposure is obtained with GEADE
804 and IESTI. For honey, the highest exposure is obtained with GEADE. Whereas for combined exposure,
805 the highest exposure is obtained for "other children" when FACE and PRIMo are used.

806 In contrast to the chronic exposure estimate (5.1), TMDI seems to be by default not fit for purpose for
807 acute exposure calculations as these scenarios normally consider only the food with the highest intake,
808 while TMDI considers by default the whole basket. Furthermore, in the acute exposure scenario, TMDI
809 shows lower consumption figures for most foodstuffs and therefore might not protect the consumer if
810 an acute endpoint is relevant for the substance. GEADE and/or IESTI has the highest consumption
811 figures for the adult population. However, for the acute estimate, it is not possible to use only
812 European clusters, therefore the data used are from the whole world and therefore not directly
813 comparable with the European data as used in FACE and PRIMo 4 (the country resulting in the highest
814 exposure is named below the table).

815 Furthermore, JMPR and JECFA uses summary statistics, while EFSA uses individual data.

816 **6. Comparison and evaluation of the exposure models**

817 In the following, the approaches and concepts for dietary exposure assessment currently used by EMA
818 (TMDI), EFSA (FACE and PRIMo), JECFA (GECDE/GEADE) and JMPR (IEDI/ IESTI) are discussed and
819 compared with regard to the scenario assumptions, the impact of input data, and the
820 algorithms/models used. It is intended to illustrate the main pros and cons of the individual
821 approaches in order to derive recommendations for a harmonised method. This discussion also
822 addresses some other, possibly critical aspects in relation to integration of the exposure estimates into
823 the risk assessment. The methodology and conduct of risk assessments have not been systematically
824 addressed under the Commission's current mandate, but some consideration is also given to the
825 possible future alignment of approaches to risk assessment, particularly risk characterization.

826 Consumer exposure assessment is a key element of risk assessment in all regulatory frameworks
827 examined in this report and the starting point for deriving regulatory management measures, i.e. the
828 setting of MRLs. A harmonized exposure assessment is therefore of utmost importance for a
829 subsequent definition of "harmonised" regulatory measures.

830 The typical exposure scenarios used for the assessment of residues of substances in food and
831 discussed in this report are the so-called "acute" and "chronic" exposure, which refer to possible short-
832 and long-term health effects of a chemical on consumers. Both scenarios and the corresponding data,
833 tools, and models used are discussed and compared, with a focus on chronic exposure, as this is the
834 reference scenario in most cases when defining risk management measures and setting MRLs.

835 **6.1. Discussion of chronic exposure models**

836 **6.1.1. Some general remarks on concepts, assumptions and data used²⁹**

837 All five dietary exposure models discussed are used for regulatory approval purposes and MRL
838 assessments for veterinary medicinal products, feed additives or pesticides. The models that are used

²⁹ The basic considerations presented here also apply in principle to the acute exposure scenario. Here, too, the result depends essentially on the assumptions regarding relevant residues and consumption data on which the models and the calculations are based.

839 in this context are currently all based on deterministic or refined deterministic approaches. Probabilistic
840 methods are currently not used within the regulatory frameworks investigated.

841 Several types of data and assumptions are required to conduct the exposure assessment, and all have
842 an impact (to a greater or lesser extent) on the results:

- 843 • Definition of the relevant residue for assessing dietary risk: The terms used in different
844 domains to describe this residue are, for instance, "(total) residue of concern", "toxicological
845 relevant residues", "residue for dietary risk assessment" or similar; all meaning the residue
846 that may have undesired (toxicological) effects on the human consumer.³⁰

847 The definition of the residue for assessing dietary risk is the result of a hazard evaluation of a
848 substance and its metabolites/transformation products. Consideration is given to the
849 pharmacological/toxicological profile of the residue components, their relative potency,
850 pharmacokinetic/toxicokinetics parameters (e.g. bioavailability) and many other factors.
851 Although the concepts and experimental methods used are in principle comparable, they (and
852 the underlying technical guidelines) are far from being standardised between assessment
853 bodies. Therefore, depending on the extent and quality of data available and the consistency of
854 the interpretation of those data (e.g., the weight attributed to certain types of evidence or the
855 level of refinement of the hazard characterisation considered appropriate), the qualitative and
856 quantitative assessment of the "relevant residue" can vary considerably. Differences in this
857 assessment can lead to significantly different definitions for the respective relevant residue,
858 which is directly (quantitatively) reflected in the final exposure estimates.³¹

- 859 • Analytical measurements are used to determine the "relevant residue" in the various food
860 commodities at suitably specified time points (typically residue-depletion and metabolism
861 studies).

862 The residues are measured by validated analytical methods. The requirements for validation
863 are based on guidelines in the respective regulatory context. Traditionally, radiolabelled
864 methodology has been used to determine the totality of residues (e.g., combustion techniques)
865 or radiometric methods (mostly) coupled with liquid chromatography/scintillation counting
866 (HPLC/LSC) to capture and identify individual (labelled) metabolites. Increasingly, non-
867 radiometric techniques mainly based on mass spectrometry (LC/MS and LC/MS/MS also
868 GC/MS) are also used for identifying and measuring the relevant residues, including MS/MS-
869 based non-targeted approaches. The performance parameters of the analytical methods are
870 critical in order to ensure the reliability and validity of the measurements and the results
871 obtained. Validation parameters such as selectivity, range of concentrations covered, limit of
872 detection (LOD), limit of quantification (LOQ) (where applicable lower and upper limits of
873 quantification (LLOQ, ULOQ)), precision and accuracy of the methods, stability of the analytes
874 and the level down to which structural identification of metabolites is carried out³², can
875 potentially all have a considerable impact on the amount, and quality (e.g. level of detail) of
876 the data available for the assessment.

- 877 • Assumption for a residue concentration in food which would be representative for the exposure
878 scenario: The selection of the (statistically derived) concentration of the residue distribution

³⁰ The definitions are different at EMA/JECFA where typically the term residue of concern would be used (often based on a total residue approach) and JMPR/EFSA Primo where the term "residue for dietary risk assessment, typically based on a more refined selection of residue components, is used. For feed additives, terms such as "total residue" or "toxicological relevant residues" are used.

³¹ The issue has also been discussed at JECFA/JMPR level https://www.who.int/foodsafety/areas_work/chemical-risks/SR-JECFA-JMPR.pdf and there is ongoing work to revise the OECD Guideline No. 63: Guidance document on the definition of residue (as revised in 2009)

³² Acc. to VICH GL 46 e.g.100 µg/kg for individual metabolites (or for metabolites comprising > 10 % of the residue)

879 that can serve as an input for the dietary exposure model is a known source of difference
880 between the TMDI, FACE, PRIMo 4, IEDI and GECDE approaches, which alone can significantly
881 affect the quantitative exposure estimate (by a factor of several-fold). The different approaches
882 are currently using either the upper tolerance limit (or MRL), a mean plus two standard
883 deviations/highest single residue, the arithmetic mean or the median from the distribution of
884 residue concentrations³³.

- 885 • Assumption on the amount of food consumed: The models discussed (TMDI, FACE, PRIMo 4,
886 IEDI and GECDE) use different sources of data on food consumption including standard food
887 baskets-based approaches, approaches using data from food balance sheets/household budget
888 surveys and data from food consumption surveys/individual food consumption data. The
889 approach/ source used for consumption input data can have a significant impact on the result
890 of the exposure estimation as shown in chapters 4 and 5.
- 891 • For all models it is assumed that all foods consumed contain residues of a substance on a daily
892 basis (i.e., assumption that all animals are treated under authorised conditions of use with
893 animal derived food obtained at the end of the legal withdrawal periods) or that all animals
894 ingest residues of a substance via feed at the maximum expected dietary burden (for
895 pesticides). This basic assumption can be contrasted with data on the actual occurrence of
896 residues obtained through monitoring and surveillance programs. For example, for pesticides
897 such data suggest that the probability of residue occurrence and the levels of observed
898 concentrations are much lower than currently assumed in the model assumptions used.
899 Unfortunately, at the moment the residue control programs for veterinary medicinal products
900 aim to detect “the illegal administration of prohibited substances and the abusive
901 administration of approved substances” and “compliance with MRLs for residues of veterinary
902 medicinal products” and only values above the MRLs are reported. Therefore, no representative
903 occurrence data (including data below the respective MRLs) exist in the veterinary field at the
904 moment. However, usage/consumption statistics for veterinary medicinal products suggest that
905 the assumption of “all-animals-treated” represents a very pessimistic worst-case scenario.
906 Representative monitoring and surveillance data would allow for more accurate, refined
907 assessments of dietary exposure. Such data are, however, not yet available in pre-regulation
908 procedures applicable to veterinary medicinal products and feed additives or pesticides. On the
909 other hand, the use of a “conservative” assumption on the presence of residues introduces a
910 “buffer” into the dietary exposure estimates, giving some assurance that exposure is, at least,
911 not underestimated for any duration of exposure.

912 **6.1.2. Specific remarks on models using food consumption survey data** 913 **(FACE, PRIMo 4 and GECDE)**

914 While 3 of the models discussed within the expert group, FACE, PRIMo 4 and GECDE, refer to the same
915 consumption data from the Comprehensive European Food Consumption Database (Comprehensive
916 Database), they use the consumption data in different ways:

917 Residue data (occurrence data) are typically measured in and reported for raw primary commodities
918 (RPC) while the amount of food consumed also includes RPC derivatives and composite foods. To take
919 this into account, the FACE model and PRIMo 4 currently disaggregate composite foods as consumed
920 into RPCs, based on the information from the Comprehensive Database. In the exposure calculations,
921 the RPC consumption data are combined with occurrence data, typically the arithmetic mean residue +

³³ Note: the baseline assumption for all exposure models investigated is that all animals of a target species would be treated and that residues remain in all the animal-derived products at the level observed in residue studies

922 2SD (FACE) or the arithmetic mean (PRIMo 4). The mean and the highest reliable percentile (usually
923 the 95th percentile) of the distribution of individual exposures will subsequently be calculated
924 separately for each dietary survey and each subpopulation class (for details see 3.4.2.1. and 3.4.3).
925 This feature is already available in FACE and will be in PRIMo 4, which is currently under development.
926 JECFA's GECDE model for dietary exposure assessments for European populations uses summary
927 statistics of the surveys in the Comprehensive Database³⁴ (a policy for dealing with processed foods
928 has not yet been fully developed at JECFA). For the GECDE exposure calculation, the consumption
929 figures are combined with the median concentration from the residue distribution observed in the
930 residue studies. The GECDE model was developed to consider high consumers as it uses the 97.5th
931 percentile or other highest reliable percentile of the amount of chronic food consumption (consumers
932 only) for the food commodity that is the highest contributor to dietary exposure (habitual high
933 consumption of one category of food) plus the mean food consumption amount for the total population
934 for all other food categories. The output is a GECDE calculated for the general population, but GECDEs
935 may also be estimated for children and infants in case of specific toxicological concerns, or for any
936 other population groups for which data are available (for details see 3.4.4).

937 The main difference between the models in terms of consumption data is that the FACE (or PRIMo 4)
938 chronic exposure tools use (i.e., can access) food consumption data at the level of individual dietary
939 records (by country, survey and age class), whereas GECDE uses the summary statistics derived from
940 the individual records (as the corresponding database CIFOcOss does currently not contain the
941 individual data). In addition, the GECDE approach does not (currently) use a conversion from
942 composite foods to their agricultural commodity equivalents, so exposures are underestimated. This
943 underestimation typical occurs in food types that are frequently processed into composite foods (e.g.
944 milk and eggs). To obtain a more meaningful comparison that at least partially accounts for differences
945 in model inputs, some exposure calculations were performed using assumptions of the FACE tool in the
946 GECDE calculation, such as converting certain foods to raw equivalents (e.g., cheese, butter to
947 adjusted milk equivalents) and using mean + 2SD as residue inputs. These comparisons showed
948 relatively good agreement between the "modified" GECDE calculations and the maximum mean and
949 dietary HRP exposure estimates for adults using the FACE tool. However, this was examined in detail
950 only for milk (see 4.2.1). Without these adjustments, the GECDE and FACE estimates for the general
951 population/adults may differ by a factor of up to 4. However, as mentioned above, this factor is only
952 indicative, since no systematic study was performed.

953 In order to get a better understanding of the impact of different residue input values and a better
954 comparison of the consumption data, the calculations were also run with a default residue input value
955 of 1 mg/kg in all models. The results confirmed the obvious assumption that the use of different
956 consumption figures is a major source of diverging exposure estimates between the models (see 5.1).

957 An additional quantitative difference may come from the approach used to estimate exposure from
958 multiple species. In this case, FACE would use the consumption of mammalian or poultry tissues (i.e.
959 animal groups), while the PRIMo 4 (for mammalian) and GECDE (for mammalian and poultry) would
960 take the consumption figure for the respective species (e.g. bovine meat) and additional species of a
961 group would be considered additively (e.g. bovine + goat). This means that for GECDE or PRIMo 4, the
962 estimated dietary exposure automatically increases when exposure from additional mammalian species
963 is added, whereas for FACE, the dietary exposure would only increase if the residues were present in
964 the additional mammalian species at higher concentrations than in bovine meat, for example. Other

³⁴ For the purpose to estimate European GECDEs

965 pertinent differences may come from different definitions for food commodities: for example, meat
966 (EFSA, 80% muscle and 20% fat) vs. muscle (GECDE/JECFA)³⁵.

967 Another difficulty in directly comparing the results of exposure calculations lies in certain differences
968 between the population groups considered for exposure assessment: GECDEs are usually determined
969 for the general population (as an average for all subgroups of the population) and only for specific
970 subgroups (e.g. children) if specific (sub)population-specific concerns arise from the toxicological
971 profile, whereas in the FACE/PRIMo 4 methodology exposure is calculated (by default) for all
972 subgroups for which surveys are available, without prior matching of exposure scenarios and
973 toxicological endpoints. These differences can be attributed to subtle differences in the approaches to
974 risk characterisation (this cannot be discussed in detail here, but may play a role in later
975 considerations on harmonisation of risk characterisation).

976 In summary, there are differences regarding the use of food definitions ("adjusted" RPCs vs.
977 "unprocessed" RPCs³⁶), the use of consumption data (animal species, age classes and individual data
978 vs summary statistics), the input residue concentrations [median (GECDE), arithmetic mean (PRIMo 4)
979 or arithmetic mean+2SD/high residue (FACE)] and some conceptual differences as discussed above.

980 Overall, there was agreement that all three models are appropriate for assessing chronic dietary
981 exposure in the general population and specific subgroups. Compared with the GECDE approach as
982 currently used, the FACE tool (or PRIMo 4) provides more opportunities for refined estimates based on
983 consumption data at the level of individual consumers and in relation to a range of specific age groups.
984 On the other hand, it was also noted that such exposure calculations based on empirical data and the
985 conclusions derived from them may need to be updated as dietary habits change. This possibility
986 exists, of course, although it is rather theoretical (considering that consumption habits in a population
987 do not change in the short term). However, this does not undermine the scientific relevance of the
988 models but rather seems to be related with the potential regulatory consequences (i.e. adaptations of
989 the risk management) that could result from a modified exposure assessment.

990 **6.1.3. Specific remarks on the model diet based approach (TMDI)**

991 The TMDI approach is a simple and pragmatic way to estimate the possible exposure for consumers,
992 based on a model daily food basket (SFB) and the assumption that residue levels are at the maximum
993 permitted level (i.e. the MRL) in each food commodity consumed. The TMDI was used in the past by
994 most committees, at least in the field of veterinary medicinal products. From the experience gained
995 over many years of use as well as from calculations provided in this report, it seems that for the
996 general population the approach is adequately protective in most cases and overly conservative for
997 some chronic exposure scenarios.

998 Compared to approaches using information from food consumption surveys (i.e. FACE, PRIMo4 or
999 GECDE), some shortcomings were identified with the TMDI/SFB model:

- 1000 • The TMDI as it is currently used would only give an estimate for a 60 kg adult (a differentiation
1001 between age groups is not possible).
- 1002 • For some food items, the value of the SFB may significantly underestimate the real chronic
1003 consumption at least in some subpopulations. This is particularly the case for milk, eggs, and

³⁵ This issue of different food classifications was already discussed by JECFA and JMPR, https://www.who.int/foodsafety/areas_work/chemical-risks/SR-JECFA-JMPR.pdf and there is ongoing discussion at Codex on a harmonisation of this issue http://www.fao.org/fao-who-codexalimentarius/sh-proxy/zh/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252Fmeetings%252FCX-730-25%252FWDs%252Frv25_09e.pdf

³⁶ "unprocessed RPCs" means foodstuff as obtained /produced "adjusted RPCs" including processed foods

- 1004 honey, and most evident for the younger age groups (this observation is based on the data
1005 from food consumption surveys). Therefore, there is a concern regarding “overlooked”
1006 exposure risks in relation to these age groups. On the other hand, the TMDI may lead to a
1007 significant overestimation of chronic consumption and overly conservative risk characterisation
1008 in relation to consumption of edible tissues.
- 1009 • The model diet assumes that all foods derived from the same tissue type (e.g. muscle) are
1010 consumed in the same amounts, irrespective of the species, and that commodities from
1011 different species are considered to be mutually exclusive (e.g. either muscle from pigs or cattle
1012 or chicken etc.) which represents an over simplification.
 - 1013 • The use of upper tolerance limits (i.e. MRLs) as the assumption for residues remaining in food
1014 seems to be unrealistic and overly conservative in relation to a chronic exposure scenario.
 - 1015 • Options to assess specific exposure scenarios are limited as there are no consumption figures
1016 other than for the four standard tissues, milk, eggs and honey and no species-specific
1017 consumption figures.
 - 1018 • There was consensus that in specific scenarios the TMDI might be useful as an appropriate
1019 screening tool to rapidly identify potential exposure risks (e.g. for tissues), but its limitations
1020 become particularly evident when it comes to specific age groups and in relation to
1021 consumption of milk, eggs or honey.

1022 **6.1.4. Specific remarks on the “balance sheet” based model (IEDI)**

1023 „Food balance sheet” (FBS) information on food consumption relies on the estimation of the availability
1024 of food at a country level. The balance sheets present a picture of the pattern of a country's food
1025 supply during a specified reference period. It relates to the total quantity of foodstuffs produced in a
1026 country, added to the total quantity imported minus exported amounts. The information can be
1027 obtained from a global database such as the FAOSTAT database which provides access to food and
1028 agriculture data. WHO GEMS/Food provides food consumption data from National Food Consumption
1029 Surveys (NFCS) and the GEMS/Food food consumption cluster diets allow the grouping of countries
1030 ‘food balance sheets’³⁷. The per capita supply of each food item available for human consumption is
1031 calculated by dividing the respective quantity by the related data on the population actually consuming
1032 it³⁸.

1033 The exposure based on FBS (e.g., IEDI) is calculated for group clusters with similar consumption
1034 patterns by summing up residue intakes from food commodities which may contain residues from
1035 authorised uses. IEDIs are typically calculated per cluster and the highest one would be used in case of
1036 a global risk assessment.

1037 The use of food balance sheet estimates has a number of limitations:

- 1038 -FBS data reflect food availability for the average population rather than individual food consumption
- 1039 -FBS tend to underestimate food consumption and chronic dietary exposure for high consumers as it is
1040 assumed that everyone in the population eats the food, resulting in tentatively lower mean
1041 consumption amounts

³⁷ <https://www.who.int/data/gho/samples/food-cluster-diets>

³⁸ <https://www.fao.org/economic/the-statistics-division-ess/methodology/methodology-systems/supply-utilization-accounts-and-food-balance-sheets-background-information-for-your-better-understanding/en/>

1042 -FBS diets tend to underestimate food consumption for consumers of occasionally consumed foods
1043 (horse meat, certain offal) as it is assumed that everyone in the population eats the food

1044 **6.1.5. Specific remarks on collection and selection of occurrence values for** 1045 **residues**

1046 Substances that are deliberately added to food (food additives, pesticides), but also substances
1047 administered as treatment to animals, which can leave residues in food, (VMPs, feed additives) are
1048 subject to authorization/registration procedures. Therefore, data on residue concentrations (occurrence
1049 data) in food are generally available from pre-regulation residues trials. In these trials the residues are
1050 investigated under conditions of the intended use of the substance(s) or, for pesticides, in animal
1051 feeding studies investigating residues for maximum expected dietary burdens. This type of data is
1052 usually used in all exposure models investigated. The data are typically generated by
1053 sponsors/manufacturers during the pre-regulation process and relevant guidelines are available in each
1054 domain on the conduct of these studies (e.g. VICH, OECD, specific EMA/EFSA guidelines).

1055 Regarding the guidelines, differences were noted between domains with respect to study design (e.g.
1056 sampling schedules, number of samples, individual/composite samples, sample preparation/sample
1057 analysis (including LOD/LOQ)), reporting and use of data (e.g. handling of concentrations below the
1058 LOD or LOQ). These technical factors may have an influence on the residue data generated and can
1059 thereby (theoretically) have an effect on the result of the exposure estimates, although the extent and
1060 direction of these effects is difficult to predict³⁹. While there is some potential for harmonization here,
1061 it is acknowledged that the technical requirements for pre-regulation studies also depend on and are
1062 tailored to the objectives of the particular regulatory context. However, aligning technical guidance
1063 across the regulatory areas mentioned above could also have significant benefits for other reasons, as
1064 pharmacokinetics/residue and metabolism data could be (re)used, at least in part, across regulatory
1065 frameworks and for different regulatory purposes (i.e., thus avoiding repeated testing of a substance
1066 due to different regulatory requirements).

1067 It is important to note that two types of residue definitions and data are normally used. The residue
1068 definition for monitoring/enforcement purposes (so-called marker compound) and a residue definition
1069 for consideration in the dietary exposure assessment and comparison to the HBGV in the risk
1070 characterisation process, e.g., total residues or active compound plus metabolites of toxicological
1071 concern (syn. residue of concern, syn. residue for dietary risk assessment). For the exposure estimate
1072 in the context of the risk characterisation the residue of toxicological concern would be used as the
1073 relevant residue. Where only data for the marker residues are available, these are normally corrected
1074 by suitable factors to account for the relevant residues. This approach is, in principle, used in all
1075 regulatory frameworks.

1076 The selection of input values for residue concentrations is based on whether an acute or chronic dietary
1077 exposure assessment is required. In a chronic scenario, assuming that a consumer is exposed daily to
1078 the upper regulatory residue limits (e.g., MRLs) is very conservative. Therefore, it is reasonable to
1079 assume that over an extended period of time consumers will be exposed to varying residue
1080 concentrations that will average out over the long term and the resulting exposure most likely
1081 corresponds to a central value of the different concentration distributions in each food.

³⁹ Generally, the more limited the information collected on concentrations present the higher the degree of uncertainty when these observations are used to extrapolate the input value to the animal population.

1082 **6.1.6. Specific remarks on chronic exposure from "multiple uses"**

1083 When a substance is authorised in multiple domains (for multiple purposes) it is possible that residues
1084 in animal derived food are present from several uses at the same time, i.e., from veterinary medicinal
1085 products, feed additives, from pesticide use (when ingested by the animals via feed) or from biocides
1086 (used to treat the animal itself or in husbandry). While this scenario is theoretically possible, reliable
1087 empirical data on the probability, frequency and quantitative relevance of such a scenario are not
1088 available. However, it can be reasonably assumed that such a scenario can occur (at most)
1089 occasionally, but that coincidence of residue occurrence from several uses would not occur on a regular
1090 (chronic) basis.

1091 Nevertheless, the group decided to consider a "multiple use" scenario in terms of chronic exposure and
1092 has discussed proposals, all of which are based on "worst-case" assumptions due to the paucity of
1093 (empirical) data available allowing to assess on the "true" probability of such a scenario happening.

1094 It is in principle possible to use two different approaches related to the chronic exposure to residues in
1095 animal commodities from multiple uses:

- 1096 • Highest residues from veterinary medicinal products, feed additive and pesticide
- 1097 • Combined residues (sum of the all 3 uses)

1098 Similar scenarios were investigated in a study of a FAO/WHO working group with regard to combined
1099 intake of residues of veterinary medicinal products and pesticides residues (Arcella, et al. 2019⁴⁰). The
1100 result showed that marginal, but systematically higher residues occur through a combination of the
1101 residues from different uses. In Chapter 7 of this report, a proposal for a uniform approach is made,
1102 aiming at using an exposure scenario that is as simple and pragmatic as possible.

1103 Note: Aggregate exposure scenarios associated with exposures from multiple pathways and routes
1104 (e.g. dietary and non-dietary/environmental sources) or cumulative exposure to multiple chemicals
1105 (e.g., multiple chemicals with a common mechanism of toxicity) "chemical mixtures", respectively, were
1106 not considered within the framework of this mandate.

1107 **6.2. Discussion of models and calculation of acute exposure**

1108 *Note: The basic considerations for (chronic) exposure presented in 6.1.1 under "Some general remarks*
1109 *on assumptions and data used" above are in principle also valid for the acute exposure scenario. Here,*
1110 *too, the outcome is essentially dependent on the assumptions on relevant residues and consumption*
1111 *data on which the model and the calculations are based.*

1112 Acute exposure refers to specific occasions/events where a large portion of a food (e.g., edible tissue,
1113 milk, eggs, or honey) is consumed that contains high levels of residues, i.e., this is the scenario that
1114 represents "peak exposure" and it commonly considers a timeframe of one day. In such cases, an
1115 assessment based on an average daily exposure, as used for chronic dietary exposure, is not the most
1116 appropriate approach to describe the exposure risk. The "acute" exposures are compared to
1117 corresponding reference values (HBGV), which stand for possible acute health effects of a substance
1118 when ingested over a short period of time. The acute reference dose (ARfD) based on an acute Point of
1119 Departure (POD) (i.e. NOAEL or equivalent) is an internationally accepted reference value to assess
1120 acute risks. There are a number of guidelines describing the establishment of an ARfD (e.g., Solecki et
1121 al. 2005; VICH 2015, OECD. 2010, FAO/WHO. 2016.)

⁴⁰ Arcella D. et al (2019). Harmonized methodology to assess chronic dietary exposure to residues from compounds used as pesticide and veterinary drug. Crit Rev Toxicol;49(1):1-10. doi: 10.1080/10408444.2019.1578729

1122 Acute assessments may be specifically relevant for pharmacologically active compounds used as
1123 veterinary medicinal products or feed additives (for the pharmacologically active substances assessed
1124 so far by the EMA/CVMP ~19% of ADIs were based on acute endpoints, ~37% on subacute endpoints,
1125 ~21% on subchronic endpoints and only ~23% on long-term (chronic) endpoints).⁴¹ Substances with
1126 specific acute pharmacological/toxicological properties may also include compounds that can trigger
1127 acute hypersensitivity reactions (e.g. penicillins). On the other hand, an acute exposure assessment is
1128 only necessary if the toxicological profile suggests a relevant acute effect. An ARfD would not be
1129 established and acute exposure would not be calculated if the acute toxicity is so low that there is not
1130 a concern (i.e., the threshold or POD of the acute toxicological endpoint is so high). In other words, the
1131 assessment of acute exposure is triggered by the toxicological profile of a substance and not solely by
1132 the possibility of higher exposures in certain situations.⁴²

1133 Acute exposure estimates are typically performed for each food commodity separately, as it is
1134 considered unlikely that an individual would consume, within a meal or within 24 hours, several large
1135 portions of different commodities that contain the same residue at a high-end residue concentration.
1136 The consumption data for acute exposure scenarios used by EFSA, JECFA and JMPR are usually derived
1137 from the same dietary surveys as those used in the chronic assessment. However, the data are used
1138 differently: for the acute estimate, data for consumers only from single days are used, leading to
1139 higher consumption figures. As described for the chronic consumption figures, EFSA uses data on an
1140 individual base whereas JECFA and JMPR would use summary statistics. Additionally, PRIMo 4 uses a
1141 different level of aggregation than FACE (e.g. mammals vs bovine, goat, sheep). Furthermore, in the
1142 database of JECFA and JMPR it is, at the moment, not intended to calculate the acute exposure for the
1143 European population only. These differences can lead to different exposure estimates, even if the input
1144 value for the residue is the same, as shown in chapter 5.2.

1145 In addition, the models currently use different residue input values (e.g., upper end of concentration
1146 range/highest reported values, high percentile/upper 95/95th percentile, observed maximum, or
1147 mean+2SD). This can lead to inconsistent acute exposure estimates, even with the same assumptions
1148 regarding food consumption. Although the concepts examined were all very similar (with the exception
1149 of the TMDI), in the interest of further harmonization, a preferred method should be agreed upon if
1150 possible. The group has developed a proposal for this, which is described in chapter 7.2.3.

1151 **6.2.1. Note regarding use of a TMDI approach in acute exposure** 1152 **assessments**

1153 The TMDI is traditionally considered a conservative screening tool for "worst-case" residue intake, as it
1154 is considered conservative enough to cover acute exposure to some extent. However, as shown in the
1155 calculations above (4.3 and 5.2), the TMDI does not appear to be conservative enough to cover acute
1156 exposure in every scenario, especially for individual food products or for certain subgroups of the
1157 population.

⁴¹ The EMA does not use an acute HBGV such as the ARfD but the ADI would be based on acute endpoints where the toxicological profile suggests acute effects as the most sensitive effects

⁴² The FAO/WHO has established for veterinary medicinal products and pesticides so-called "cut-off" values above which setting of an ARfD and an acute assessment would not be necessary. The JMPR has proposed a human acute toxicity threshold for pesticides of 5 mg/kg body weight, above which an ARfD would not be required. Following the same principles, a corresponding calculation was made for veterinary medicinal products. The highest MRLs/tolerances established in Codex, the EU, and the U.S. were used, as well as the 97.5th percentile of the highest consumption (consumer only, on one day) for each edible tissue. Taking into account the uncertainty in this estimate, the result was a limit of 1 mg/kg that would be appropriate for establishing an ARfD for veterinary medicinal products residues. The values should just illustrate as to when an exposure scenario for the acute effects may be needed (source http://www.who.int/foodsafety/chem/jecfa/Guidance_ARfD.pdf).

1158 **6.3. Note regarding "less-than-life-time" approach**

1159 For completeness, the so-called "less-than-lifetime" scenario will be mentioned here as an exposure
1160 scenario, which may occasionally require consideration in food safety assessments in addition to the
1161 acute and chronic assessment. A "less-than-lifetime" assessment would be triggered as a result of a
1162 specific toxicological profile of a substance and a specific exposure situation: Exposure can occur over
1163 periods longer than one day (acute) but less than a lifetime (chronic). Such exposures may be
1164 continuous or intermittent for a certain period of time during life. When assessing "chronic" risks the
1165 baseline assumption is that exposure peaks or occasional fluctuations/excursions above the "chronic"
1166 HBGV (i.e. the ADI) would be balanced out by lower intakes at other times and that the average
1167 exposure per day over the entire lifetime would determine the outcome. Certain exposure risks may,
1168 however, be underestimated if exposure over shorter periods (appreciably) exceeds the relevant ADI
1169 and where this ADI is based on "less -than-lifetime" health effects, as the relevant most sensitive
1170 endpoint (e.g. certain subchronic or subacute endpoints). In principle, the "less-than-lifetime" concept
1171 refers to a method to interpret and assess the risks for human health in case exposure exceeds the
1172 "chronic" HBGV. For example, in case of reproductive effects or in cases where the severity of
1173 toxicological effects underlying the ("chronic) HBGV, i.e. ADI, do not appear to progress after short
1174 periods of administration in the toxicological studies (e.g., after 2–3 months). These exposure risks
1175 and endpoints may be not adequately covered by the acute risk assessment (as the endpoint for acute
1176 hazards may be different) and the "averaged" chronic exposure over lifetime may underestimate this
1177 type of short-term exposure. The concept of "less-than-lifetime" exposure is a relevant concept but
1178 has not yet consistently found its way into the regulatory processes of risk assessment, or only to a
1179 limited extent (is partly used at JECFA and JMPR).

1180 In this context, it seems worth noting that exposure models that use a range of relevant
1181 subpopulations or consumption information differentiated by age groups generate information that can
1182 be used for more accurate risk assessment in potentially vulnerable time windows of exposure.
1183 However, the group did not really discuss these issues in the context of a "true" less-than-lifetime
1184 approach, nor did it discuss the less-than-lifetime exposure concept in any depth and detail necessary
1185 to make recommendations and draw conclusions in light of the mandate. This could be explored in a
1186 follow-up investigation that would consider risk characterization methods in more detail and develop
1187 proposals for appropriate harmonization. See also the discussion under 7.2.

1188 **6.4. Note regarding possibilities to use JECFA and JMPR models**

1189 The JECFA and JMPR approaches aim at global harmonization and standard setting and therefore rely
1190 on global data on substance use, residue occurrence and consumption data. Since consumption
1191 patterns differ from country to country, as do the approved uses of substances, the results of this
1192 assessment cannot be directly applied to the specific European situation, or can only be partially
1193 applied. However, the algorithms and models used can be applied without restriction to European data,
1194 and the methods in this report have been compared (where possible) with JECFA and JMPR calculations
1195 based on EU data. Regarding consumption data, EFSA has individual data in the Comprehensive
1196 Database from the national surveys, while JECFA, for example, only has summary statistics for the
1197 same data in the CIFOcOss database. These limitations in data use, apart from differences in
1198 calculation models themselves, have somewhat affected the direct comparability of results. However,
1199 as noted above, experts agree that individual data are more accurate from a scientific perspective and
1200 should be used whenever possible.

1201 **7. Summary and recommendations**

1202 This report presents findings, conclusions and recommendations resulting from a comparison of
1203 different exposure models currently used by EMA, EFSA, JECFA and JMPR to assess residues of
1204 veterinary medicinal products (EMA, JECFA), feed additives (EFSA, JECFA) and pesticides (EFSA, JMPR)
1205 in animal-derived food. The analysis included the major models for both short-term (acute) and long-
1206 term (chronic) exposure estimates. Other exposure concepts that are used in certain situations (e.g.,
1207 "less-than-lifetime") were discussed only marginally and were not included in the comparison because
1208 they are not yet universally established in the regulatory context and were also not considered
1209 sufficiently developed to be included in a harmonized recommendation.

1210 **7.1. Lessons learned**

1211 Consumer risk assessment for residues of veterinary medicines, feed additive and pesticides are
1212 conducted in different legislative/regulatory frameworks in the EU and the methodologies used, while
1213 based on common principles and pursuing the same objectives, namely consumer protection, differ in
1214 their scientific approaches and practice. Also, at Codex Alimentarius level, exposure assessment
1215 approaches for food additives/veterinary medicinal products and pesticides differ between Codex
1216 Committees (CCRVDF, CCPR) and their respective expert committees (JECFA, JMPR).

1217 Some of the observed differences can, of course, be attributed to certain differences in regulatory or
1218 legislative provisions and requirements (and corresponding guidelines), but to a significant extent
1219 differences were simply attributable to differences in the scientific models, scientific assumptions and
1220 types of consumption and occurrence data used. Many of these differences in approaches cannot really
1221 be explained "scientifically" but are possibly due to a historically largely independent (asynchronous)
1222 development of the scientific procedures and practices in each domain.

1223 The expert group has examined the potential for harmonisation or alignment of procedures, with a
1224 main focus on exposure assessment methodologies for animal derived food for VMPs, feed additives
1225 and pesticides. This included the methods used at European level (EFSA/EMA) and the approaches
1226 currently used in Codex Committees for food additives/veterinary medicinal products and pesticides
1227 (JECFA/JMPR).

1228 Exposure assessment requires data on chemical analysis of the residues in food matrices (so-called
1229 occurrence data), an estimate of daily consumption of food by consumers, and an estimate of the
1230 potential significance to human health of the residues contributing to the exposure (i.e. description of
1231 the potential chemical hazard associated with the residues to which a consumer population is
1232 exposed), and it requires a model with which to link these data. The relevance and accuracy of the
1233 exposure assessment thus depends largely on the extent and quality of the data available, and on the
1234 way in which those data are used.

1235 The expert group has noted relevant differences between all methods and approaches currently used
1236 to gather and assess these types of data. The food consumption data used include, for instance, data
1237 of various types, such as individual food consumption data at different levels of the food chain, from
1238 raw primary commodities to processed and composite foods, data derived from food balance sheets,
1239 and hypothetical model diets.

1240 Occurrence data are typically collected in residue trials in which the chemical is administered to the
1241 animals according to label instructions or, for pesticides, at the calculated dietary burden. However,
1242 apart from the necessary differences in the study design due to different regulatory objectives of the
1243 studies, there is a number of "avoidable" more practical/technical differences concerning sampling

1244 schedules, types of tissues collected and data handling. Differences were also noted with respect to the
1245 analytical approaches used for identifying residue components/metabolites in animal commodities
1246 (total residues vs. individual residues), thresholds for (structurally) identifying metabolites, handling of
1247 bound/non-extractable residues, dealing with left censored data/non-detects etc.

1248 In the following, the possibilities of alignment of approaches are discussed with respect to the use of
1249 consumption data, the choice of input data for chronic and acute exposure, and possibilities for a
1250 harmonised estimate of a combined intake from multiple sources. There was consensus that exposure
1251 estimates should, in the first instance, be calculated separately for all (sub)populations for which
1252 relevant consumption data are available to allow an optimal characterisation of the distribution of risks
1253 among different sub-populations (adults, children etc.). The way in which this exposure information is
1254 used in risk characterization depends on the hazard profile of the residues and results of the hazard
1255 assessment (e.g., types of toxicological endpoints) but also on the level of intended granularity of the
1256 assessment in relation to different population groups. Currently, there is no consistent harmonized
1257 policy, procedure and guidance on when and how, for instance, subpopulations are considered and
1258 included in risk characterization. This is an area where further discussion and effort for alignment of
1259 principles and approaches between jurisdictions would be beneficial.

1260 **7.2. Recommendations for exposure estimation**

1261 In the following sections, recommendations are made for harmonised models, assumptions, and
1262 algorithms in the exposure estimation. Recommendations concerning the implementation of these
1263 concepts in the risk assessment process are not made, but it is expected that implementation of
1264 harmonised approaches to exposure estimates will also promote certain adjustments to the concepts of
1265 risk characterisation in the different domains and have an effect on the methodology of how regulatory
1266 standards (such as MRLs) are derived.

1267 For each element of the exposure assessment, a preferred method that can form the basis for a
1268 harmonised methodology ("preferred method") is proposed, as well as reasonable alternative options
1269 ("reasonable alternative") which, according to the group's findings, can be expected to produce
1270 comparable and acceptable results within the variability and uncertainties inherent in such an estimate.

1271

1272 Where recommendations are made for specific methods to be used in the future, these, of course,
1273 refer to the EU procedures in the context of the evaluation and approval of veterinary medicinal
1274 products, feed additives and pesticides. Although JECFA/JMPR methods were included in the analysis,
1275 this was more for comparison purposes and to explore possible advantages and benefits of these
1276 models.

1277 A recommendation regarding the future use of specific "harmonized" models for FAO/WHO expert
1278 groups is, of course, outside the EU mandate. However, it would be desirable if JECFA and JMPR take
1279 into account the suggestions made here in their own harmonization efforts and with a view to the
1280 setting international standards.

1281 **7.2.1. Proposal for harmonisation in consumption data used**

1282 One of the objectives of the mandate was to identify a single reasonably accurate and acceptable
1283 model to be used in exposure assessment and to recommend it as a base model for exposure
1284 calculations in the EU and to identify the most appropriate food consumption data to be used. The
1285 currently used models are described in detail in chapter 3.4.2-3.4.4 and were considered by the expert
1286 working group.

1287 **Proposal for use of consumption data for animal derived food**

1288 **Preferred source:**

1289 Consumption data based on surveys in the EFSA's "Comprehensive Database" as transformed into data
1290 on raw primary commodities (RPC) are considered as the preferred source, as it is considered the most
1291 relevant and accurate one for the European population. The data should be made available in the most
1292 detailed (disaggregated) way possible, e.g. to allow for "offal" to be differentiated in to liver and
1293 kidney.⁴³

1294 **Reasonable alternatives:**

1295 CIFOCoss data: The data base contains consumption data from surveys on a global scale. Concerning
1296 data from EU member states, only "summary statistics" from EFSA's "Comprehensive Database" are
1297 available in CIFOCoss (i.e. based on the same data). Currently transformation of data into RPCs is not
1298 used, which may cause bias when compared with data from residue studies.

1299 **7.2.2. Proposal for harmonised residue (occurrence) input assumptions for**
1300 **acute and chronic exposure**

1301 **Chronic exposure**

1302 In a chronic exposure scenario, it is recommended to preferably use the arithmetic mean of residue
1303 concentrations in relevant animal-derived food as an estimator for the daily intake:

1304 The information on the possible residue occurrence in animal-derived food is usually obtained in (pre-
1305 authorisation) residue studies and the expected daily residue intake is derived from the distribution of
1306 residues in these samples⁴⁴. The number of samples per time point(s) obtained in such studies is often
1307 quite small (e.g., for VMP generally less than 30 animals in total, distributed over 4 to 5 slaughter
1308 days), and in most cases no "rigorous" assumptions can be made about the "true" statistical
1309 distribution of residues at a given time point. For convenience, the assumption of a normal distribution
1310 of concentrations is therefore used as the default assumption in most cases, knowing that the actual
1311 distribution may also be asymmetric, e.g. right-skewed (or left-skewed) or even multimodal, as a
1312 result of a mixture of different distributions, which, however, would only be apparent if the whole
1313 population could be observed.⁴⁵

1314 For concentration data with unknown distribution of residues, i.e. where only the empirical distribution
1315 is known, the assumption of an approximate normal distribution with the arithmetic mean of the
1316 available sample as the expected value is considered a most reasonable recommendation.

1317 However, because occurrence data are subject to multiple random errors mostly due to the combined
1318 effects of sampling error (i.e. biological variability and limited sample size) and measurement
1319 uncertainty, the arithmetic mean might lack of the adequate precision and accuracy. The associated
1320 uncertainty can be accounted for by determining a (1- α) confidence interval for the arithmetic mean
1321 (common choices are 90% or 95% confidence).

⁴³ This statement is based on the understanding that the consumption data in FACE and PRIMo 4 are currently prepared with different levels of detail. In principle, with a view to maximum flexibility and adaptation to different regulatory requirements, the most differentiated data basis is to be preferred

⁴⁴ a suitable time for the choice of values is, for example, the time when residue fall below the MRL, i.e. when the food can be legally placed on the market

⁴⁵ as far as is known, the distribution of residue concentrations in edible tissues in a sufficiently large sample of animals has never been described in the literature

1322 As uncertainty extends in both directions around the mean, the "true" value can be either higher or
1323 lower than the range of measured values. Using the upper/lower boundary for the occurrence
1324 estimates, it can be assumed with probability $(1-\alpha/2)$ that the "true" occurrence value is below/above
1325 this value. As the confidence limit is predominately linked to the number of samples as well as the
1326 variability, it will be closer to the mean, the more robust the data are. It is recommended to always
1327 report the mean value together with the corresponding uncertainty ranges to give the risk assessor
1328 and risk manager an approximate estimate of the uncertainty interval of the occurrence values. For
1329 exposure calculations, it is justified to choose occurrence values from this range, depending on the
1330 level of uncertainty that is considered acceptable for the purpose and use of the assessment.

1331 Typically, if a reasonably sufficient number of observations are available and the variability of the data
1332 is relatively small, the (arithmetic) mean can be taken. A further aspect to this consideration may be
1333 that the use of residue occurrence data is inherently based on the conservative assumption that all
1334 animals are treated under the approved conditions of use with food derived from animals obtained at
1335 the end of the prescribed withdrawal periods or that all animals ingest residues of a substance through
1336 their feed at the level of maximum expected dietary exposure (for pesticides).

1337 However, depending on the quality of the data it may be necessary to use values based on the upper
1338 90 % (or 95 %) confidence limit of the arithmetic mean for the occurrence in the exposure
1339 assessment, in particular if only few observations are available and the number of animals sacrificed in
1340 a trial cannot be increased due to ethical and economic considerations or if, for example, the
1341 occasional intake of increased (fluctuating) residues is a concern due to the specific toxicological profile
1342 (e.g. ADI based on subchronic effect or other short-term effect). This is to be decided on a case-by-
1343 case basis. In such cases, care should be taken not to underestimate by choosing the mean and the
1344 upper confidence levels should be taken.

1345 Where pharmacokinetic data are available, i.e. data on the depletion of residues over time, suitable
1346 mean values and corresponding confidence limits may also be derived from modelling the data using
1347 e.g. regression analysis, in order to make better use of all available data.

1348 The suitability of the median (used in some models, e.g. GECDE) as a standard estimate for chronic
1349 exposure may be questioned on the basis that the rules for finding the median tend to ignore relevant
1350 occurrence values: the median is not impacted by values at the (extreme) high end of the dataset (and
1351 also not impacted by low end values).

1352 Also the geometric mean would not sufficiently account for "high end" values as it tends to be more
1353 sensitive to smaller numbers than larger numbers (making it relatively insensitive to high occurrence
1354 values).

1355 The 95/95 tolerance limit, i.e. upper one-sided 95% confidence limit over the 95th percentile residue
1356 concentration, which is commonly used by EMA can be regarded as very conservative when assessing
1357 chronic exposure since use of this value assumes, unrealistically, that on each day the residues are in
1358 the range of >95% of possible residues.

1359

1360 **Proposal for "chronic" residue input assumptions**

1361

1362 **Preferred model:**

1363 For the chronic exposure a value based on the arithmetic mean is recommended. The arithmetic mean
1364 of a limited sample comes along with uncertainty due to the randomness of the sample and the
1365 variability in the total population. This uncertainty can be described by considering a lower and upper

1366 90% (or 95%) confidence limit of the mean⁴⁶. All three values (mean, upper and lower confidence
1367 limit) should be calculated to obtain a range of possible occurrence data for further use in the exposure
1368 models or further risk assessment/risk management.

1369 **Reasonable alternatives:**

1370 If quality of data does not allow for use of the upper limit of the confidence interval of the arithmetic
1371 mean (e.g., data not fulfilling the basic statistical criteria), a scientifically justified alternative value
1372 may be used. This could either be the arithmetic mean and (alternative) term(s) to account for
1373 uncertainty or the arithmetic mean itself, if justified for the scenario under consideration.

1374

1375 Note: if the data do not allow for a quantitative (statistical) assessment of associated uncertainties,
1376 this limitation should be clearly identified to allow for an assessment of the potential impact on the
1377 overall outcome (and to manage this through a more cautious and conservative approach).

1378 **Acute exposure**

1379 For the acute exposure, it is relevant to include the most conservative residue value at the top-end of
1380 the residue distribution. It may be considered to use the upper 95 % tolerance limit (with 95%
1381 confidence) or the MRL as a "worst-case" assumption for residues present. If there are insufficient data
1382 to calculate a 95 % tolerance limit (with 95% confidence), then the maximum (highest) reported
1383 residue level from a study or the mean + 2SD could be used.

1384 In the pesticide field it is usually assumed, that for blended commodities (e.g. milk) the mean residue
1385 value would be the reasonable input value for the acute exposure. Values at the (extreme) high (and
1386 low) end of the dataset do not seem to be of importance, because of dilution effects in bulk milk.
1387 However, this assumption may not be true for all situations in the veterinary field, as milk can be
1388 obtained directly at farm level and some products are intended to be used in the entire livestock.

1389 **Proposal for "acute" residue input assumptions**

1390 **Preferred:**

1391 It is recommended to use the upper 95% tolerance limit (with 95% confidence)⁴⁷, which is mostly the
1392 same value as the MRL as a "worst-case" assumption for residues present.

1393

1394 **Reasonable alternatives:**

1395 If there are insufficient data to calculate an upper 95% tolerance limit (with 95% confidence), then the
1396 maximum (highest) reported residue level from a study or mean + 2SD could be used.

1397 In fields where it can reasonably be assumed that a foodstuff (e.g. milk) is always blended, mean
1398 residues can be used as input values.

⁴⁶ confidence limits = mean(X) ± k' × sd(X)
with

$$k' = \frac{t_{n-1,1-\alpha/2}}{\sqrt{n}}$$

where $t_{n-1,1-\alpha/2}$ is the (1- $\alpha/2$) percentile of Student's t -distribution with $n-1$ degrees of freedom.

⁴⁷ tolerance limit = mean(X) + k × sd(X)
with

$$k = \frac{t_{n-1,1-\alpha}(\delta)}{\sqrt{n}}$$

where $t_{n-1,1-\alpha}(\delta)$ is the (1- α) percentile of the non-central t -distribution with $n-1$ degrees of freedom and non-centrality parameter $\delta = z_p \times \sqrt{n}$ (z_p the P^{th} percentile of the standard normal distribution).

1400 **7.2.3. Proposal for harmonised exposure model**

1401 The exposure modelling concepts discussed and compared in this report are all based on deterministic
1402 exposure estimates, but with varying degrees of refinement. The recommendation is based on the most
1403 refined (advanced) deterministic model(s) currently used at EFSA, EMA, JMPR or JECFA. The model inputs
1404 are derived from empirical consumption and occurrence data as outlined in the sections above.

1405 **Proposal for “chronic” exposure model**

1406 **Preferred:**

1407 The preferred model should be based on i) individual-level dietary surveys (preferably using RPC
1408 values), ii) provide information on exposure in different subpopulations/age groups (e.g. infants, young
1409 children, adults), and iii) allow estimation of exposure levels at different levels of the exposure
1410 distribution (e.g. 95th percentile or other values of interest). The more refined the model, the more
1411 options there are for specific and relevant risk assessments.⁴⁸

1412 **Reasonable alternatives:**

1413 Another suitable model is based on food consumption distribution (GECDE model), assuming
1414 consumption for one food category at a high level (e.g. 97.5th percentile consumption) and mean
1415 consumption for all other categories. It can be used to calculate exposure for the general population and
1416 population subgroups, as needed. The model uses summary statistics from the EFSA comprehensive
1417 database.

1421 **Proposal for “acute” exposure model**

1422 **Preferred:**

1423 The preferred model should allow for separate estimates based on individual dietary surveys and single
1424 food commodities (preferably using RPC values). The relevant residue input value for the commodity
1425 being assessed is combined with the corresponding total consumption of the commodity on each
1426 individual day for this purpose. Higher percentile exposures (usually the 97.5th percentile) based only
1427 on days of consumption are calculated separately for each food, dietary survey and age group (e.g.
1428 infants, young children, adults).

1430 **Reasonable alternatives:**

1431 If no individual consumption data are available, summary statistics of dietary surveys could be used.
1432 The relevant residue input value is combined with a high daily consumption (97.5th percentile) of that
1433 food (meat, offal, milk, others).

1435 **7.2.4. Proposal for combining “chronic” exposure to residues from multiple** 1436 **uses in animal tissues**

1437 When compounds are used as pesticides, as veterinary medicinal products and/or feed additives
1438 (dual/triple-use compounds), residues may theoretically be present in animal commodities resulting
1439 from the use of the compound in all three domains (from direct use as VMP or food additive through
1440 the labelled route of application or from exposure of the animal via plant derived feed). In this case,
1441 the working group assumed that residues will be present in 100% of all animal commodities from all

⁴⁸ It should be borne in mind that all models compared here are based on deterministic models used in the regulatory field and higher tier probabilistic models are currently not included in the discussion.

1442 uses. This is consistent with the assumption currently used for the separate assessments of veterinary
1443 medicinal products /feed additives and pesticides. The probability for this worst case to take place was
1444 however seen as very unlikely, which is inter alia evident from monitoring/surveillance data or
1445 treatment records. In the absence of accurate information on the "true" occurrence of residue from
1446 multiple uses, a pragmatic (still conservative) approach would be to use the highest mean observed
1447 residue from each species/commodity for the chronic exposure. For acute exposure this would be the
1448 highest acute exposure estimate from all three uses.

Proposal for "combining" residues from multiple uses

Preferred model:

1452 Identify and use the highest mean observed residue per commodity/species from all uses for the
1453 chronic exposure. As the arithmetic mean of a limited sample comes along with uncertainty due to the
1454 randomness of the sample and the variability in the total population, this uncertainty can be accounted
1455 for by considering the upper 90% (or 95%) confidence limit of the mean. By doing so, it may be
1456 assumed that also subchronic endpoints are adequately covered.

1457 For acute exposure apply the highest acute exposure estimate out of all three uses, if applicable

Reasonable alternatives:

1460 There are currently no alternative deterministic methods. It is theoretically possible to better estimate
1461 such scenarios on the basis of probabilistic methods, but there is currently no sufficient data base or
1462 established models available for this.

Other options:

1465 Addition of mean residues (for chronic) or highest residues (for acute) from all three uses: however,
1466 this would lead to unrealistically high estimates.

7.2.5. Proposal for harmonisation of some of technical aspects of the exposure approaches

Definition of tissues

1470 The experts noted some differences in the classification/definition of tissues in the different models
1471 (e.g. use of a definition of meat (EFSA) as opposed to muscle (EMA/JECFA)), which can lead to
1472 different input quantities for the models. There were also some similar differences noted in the
1473 definition and use of offal tissues in the exposure estimates.

1474 It was noted that some of these differences are due to historical rather than explicit scientific reasons.
1475 In some cases, however, these differences have a scientific basis. Whereas residue studies will
1476 investigate samples of muscle tissue and/or fat, the food consumption data used by EFSA refer to meat
1477 consumption, which may include consumption of trimmable fat. EFSA therefore uses some standard
1478 assumptions to "convert" tissue types and corresponding residue concentrations by way of calculations
1479 (e.g. residues in "meat" being a mixture of 20% fat and 80% muscle vs residues in muscle or fat).
1480 However, the group did not perform specific calculations on the quantitative impact of these
1481 differences on exposure nor did it elaborate a concrete proposal for harmonisation.

1482 The group also noted that there is ongoing work at Codex level (CCPR, CCRVDF) on the harmonisation
1483 of definitions for edible tissues/food of animal origin for compounds with multiple uses.

Estimating exposure from multiple species

1485 The group noted that in exposure estimates from multiple species consumption data are partly used in
1486 different ways and levels of aggregation: for example, grouping of different species (mammals) in
1487 FACE vs "cattle, sheep, goat" in PRIMo 4 (or for the JECFA models) (see 3.4.3.2.). A high-level
1488 aggregation of food consumption data (e.g. one consumption factor/input value for mammals) may on
1489 one hand simplify the exposure assessment, but on the other hand there might be situations where
1490 exposure assessment at the individual animal species is required or preferred to obtain more accurate
1491 estimates.

1492 **7.2.6. Thoughts on a harmonised use of exposure estimates in risk** 1493 **characterisation approaches**

1494 Risk characterization combines quantitative exposure assessments and results from hazard assessment
1495 to draw conclusions about the likelihood and magnitude of potential health effects, associated
1496 uncertainties, and options for reducing or avoiding risks. It starts with and is based on scientific data
1497 and scientific models, but also involves certain default assumptions based on expert judgment and
1498 policy choices.

1499 It is not the intention here to go deeper into the complex mechanisms and the various aspects of
1500 decision making in risk characterization, as this would go far beyond the scope of the mandate. Only
1501 some specific aspects on the use and integration of exposure estimates into risk characterisation will
1502 be highlighted here.

1503 Based on the review of the different approaches to exposure assessment and the comparison of the
1504 models used, the expert group unanimously concluded that both short-term and long-term exposure
1505 scenarios should be assessed in the risk characterisation.

1506 It is of critical importance to the outcome of the risk characterisation how these exposures are used in
1507 the process. This includes not only an evaluation of the suitability of the individual exposure scenarios
1508 themselves, but also of the nature and character of the health-based guidance value (HBGV), i.e., the
1509 underlying health effects. For example, for the assessment of chronic exposures, the ADI is used as
1510 the default HBGV in all of the regulatory frameworks reviewed. The traditional basic assumption is that
1511 the ADI value, according to its definition, covers the health effects of a consumer's daily exposure
1512 throughout life and is protective across all life stages, i.e., that the average long-term exposure as
1513 presented in the estimates for the general or adult population (most life stages consist of the adult
1514 phase) would be appropriate.

1515 However, the pattern of toxicological effects may indicate that particular life stages or subgroups may
1516 be at higher risk than the average population, and in these cases, life stage/subgroup specific risk
1517 characterisation could provide a more accurate match between the nature of the toxicological effect
1518 and the specific exposure situation (e.g., infants, children, elderly) and greatly improve the quality and
1519 relevance (i.e., safety) of the assessment. In short, the more detailed and differentiated the exposure
1520 assessment is with respect to multiple exposure scenarios, life-stages, population groups, prediction of
1521 exposure ranges, the more options will be available to the risk assessor and the more flexible,
1522 accurate, and reliable the risk characterisation can become. In the discussion, a number of
1523 considerations were made in this regard that could guide further development of approaches:

- 1524 • One advantage of the FACE and PRIMo models is that detailed exposure estimates can be
1525 generated for a range of subpopulations/age groups and at different exposure levels (e.g., mean, 95th
1526 percentile) which may then be specifically and relatively precisely matched to the hazard (toxicological)
1527 profile of interest.

1528 • The GECDE model is, in principle, also sufficiently flexible and capable of calculating exposure
1529 for specific subpopulations, life stages and high consumer groups, if required for specific toxicological
1530 reasons.

1531 • The IEDI model is a model for estimating approximate average chronic (lifetime) exposure and
1532 refers to a general population, but is not suitable to identify specific consumption patterns and, thus
1533 not accurate and flexible enough for estimating exposure in certain subpopulations and life stages

1534 • The TMDI model is based on a food basket for 60 kg adults and is not suitable to be used as an
1535 exposure model for risk assessment of specific subpopulations or to cover specific consumption
1536 patterns in certain subpopulations and life stages.

1537 As noted above, exposure assessment is only one building block of risk characterization, and a
1538 uniform, valid scientific methodology for collecting, analysing, and using exposure data (the same is
1539 true for hazard data) would not guarantee a consistent outcome of risk characterization because a
1540 range of default assumptions, conventions, expert judgments (and policy choices) are applied at this
1541 step of interpreting the scientific evidence. However, input based on the best possible scientific data
1542 and the best possible scientific models can greatly increase the likelihood of consistent (harmonized)
1543 results.

1544 **8. Conclusions and Outlook**

1545 This work is based on a mandate from the EU Commission requesting scientific and technical
1546 assistance from EFSA and EMA to develop a common approach to exposure assessment methods for
1547 residues of veterinary medicines, feed additives and pesticide residues in food of animal origin. The
1548 mandate was received in July 2020.

1549 The work was carried out by a joint EMA/EFSA working group (Enlarged Working Group on Exposure
1550 Assessment), which was established in December 2020 and included experts nominated by EFSA and
1551 EMA and, in addition, experts working for JMPR and JECFA.

1552 The expert group has compared the methods and models used in the different domains in terms of
1553 data sets used, theoretical assumptions and calculation models, and carried out a series of
1554 comparative calculations to identify and quantify differences and the factors influencing the respective
1555 results. This work is presented and discussed in detail in chapters 1-6 of this report.

1556 The differences between the exposure assessment methods examined could be primarily attributed to
1557 the type and use of consumption and occurrence data, but also to the calculation models and the
1558 desired level of refinement and detail of the assessments (i.e. the choice/use of methodological tier).
1559 While certain differences in the generation and handling of the data were identified, a number of
1560 differences can also be explained by a historically largely independent (i.e. asynchronous) scientific
1561 development of exposure assessment methodologies in the various domains.

1562 Due to the complexity and multi-layered nature of the various aspects and questions to be addressed,
1563 most of the discussions took place ("intentionally") at a relatively high level of abstraction to allow for
1564 the identification and comparison of key concepts and key features of the different methodologies,
1565 rather than putting too much effort into clarification and agreement at the level of technical detail and
1566 terms.

1567 The outcome of the work should therefore be seen as the group's agreement on the basic "building
1568 blocks" of a recommendable harmonised methodology, rather than a ready-to-use methodology,
1569 worked out to the last technical detail and directly operational in each regulatory domain. For this

1570 reason, many downstream technical aspects and specificities were left out of the discussion for the
1571 time being.

1572 Following this approach, a set of recommendations was developed outlining the key elements of what
1573 would constitute the "preferred methodology" (i.e. data sources and models). However, for each
1574 proposal, an alternative proposal was also developed. The guiding principle in all of this was to obtain
1575 the most realistic exposure assessment possible based on the available methodologies, i.e. to use the
1576 most specific input data and modelling assumptions that allow for a relatively high level of refinement
1577 and detail in the results, thus providing a range of options and flexibility to ensure a sufficiently specific
1578 and relevant risk characterisation.

1579 The recommendations relate to the following aspects (see chapter 7 of this report):

- 1580 • selection of consumption data
- 1581 • selection of occurrence data
- 1582 • selection of exposure model(s)
- 1583 • exposure to residues from multiple uses
- 1584 • use of commodity definitions and combined exposure from multiple species

1585 These recommendations of the group could in principle form the "blueprint" for a future harmonised
1586 methodology. The group was also aware that if the recommendations were adopted, a number of
1587 follow-up actions would be needed to further define, elaborate and consolidate the harmonised
1588 methodology, especially at the technical level of detail, and to fit it into the respective risk assessment
1589 approaches and the legal frameworks. Some other issues related to the use of uniform definitions,
1590 terminology and the alignment of scientific guidelines, which were not considered as part of this
1591 activity, should be included in the follow-up work.

1592 The group's recommendations focus primarily on exposure assessment as the usual first step of a risk
1593 assessment rather than the use of exposure assessment data in the subsequent steps of the risk
1594 characterisation. Although some aspects of the risk characterisation were discussed, no
1595 recommendations were developed under the current mandate.

1596 As a starting point, the group agreed to include in the comparison only those exposure assessment
1597 methods that are (currently) actually used in the regulatory areas for residues of veterinary medicinal
1598 products, feed additives and pesticides. As mentioned above, all these methods are based on
1599 traditional deterministic approaches, using varying degrees of refinement. Agreement on the "best
1600 possible" existing methodology or on a reasonable combination of the "best possible components" of
1601 existing methods and models were considered an important step towards harmonisation.

1602 However, this does not mean that possibilities for further scientific optimisation and meaningful
1603 extension of the methods or integration of further tools into the existing approaches were not
1604 discussed, i.e. the perspectives on how a "harmonised" methodology could be further developed and
1605 refined to answer additional questions related to exposure assessments in the future. Here, the group
1606 has made some initial considerations, which are by no means to be regarded as comprehensive or
1607 conclusive. None of these aspects or options are currently integrated into existing standard
1608 methodologies, so these suggestions should be seen solely in terms of future developments:

1609 - Combined exposure assessment: The harmonised methodology for tissues could be extended to allow
1610 for assessment of exposure to substances with multiple uses, i.e. combined assessments of chronic
1611 dietary exposure from animal plus plant derived foods, and in a subsequent step it might be considered

1612 to also integrate cumulative combined exposure (i.e. multiple sources) to substances belonging to
1613 groups with a common mechanism of toxicity.

1614 - Use of monitoring data: The exposure estimates currently conducted are based on residue data from
1615 pre-authorisation studies conducted under the intended conditions of use. The assumptions underlying
1616 the study design are intentionally conservative, and the results may not accurately reflect the "real-
1617 life" residues in food as they are available on the market⁴⁹. Data from monitoring and surveillance
1618 programs (post-market) may be more appropriate here, as they provide information on levels and
1619 occurrence frequencies of residues in food as they are actually ingested by consumers. However,
1620 monitoring data are often based on targeted sampling for enforcement purposes (to demonstrate
1621 compliance/non-compliance with legal uses) and are therefore often not sufficiently representative for
1622 the background exposure. Therefore, it would be desirable to have truly representative data available
1623 based on samples from a representative random sampling design, ideally using modern analytical
1624 methods able to detect a broad range of residue components (i.e., including relevant metabolites).
1625 Where such data are available, it may be appropriate to revisit exposure estimates at appropriate
1626 times after approval to refine the original exposure estimate.

1627 - Consideration of ADME/pharmaco-/toxicokinetic data: Current exposure assessments only address
1628 external exposure (via oral intake), while options that consider internal (systemic) exposure, i.e. the
1629 actual amount of substance released from food matrix and absorbed/acting in the human body, which
1630 would allow the best possible comparison with toxicological effects in the context of risk
1631 characterisations, are usually not considered. Existing toxicokinetic information, in particular on the
1632 (relative) bioavailability/bioaccessibility of residues from the food matrix, could be included in a
1633 harmonised assessment approach, which could lead to a more realistic assessment in many cases.⁵⁰

1634 - Consideration of food processing: Most food is consumed in processed form (e.g. cooking/baking,
1635 pasteurisation, also ageing), which not only affects the concentrations found, but in part also the
1636 qualitative composition of the residues, i.e. the type of residues (incl. de-toxication as well as
1637 toxication reactions). The residues formed or possibly changed under these conditions are not or not
1638 adequately taken into account in the usual exposure estimates which are typically based on
1639 measurements in the raw animal derived commodities. Here, too, consideration could be given to how
1640 such information could be integrated into exposure estimates to derive more accurate and relevant
1641 estimates.

1642 - Less-than-lifetime approaches: The models examined refer to acute (short-term) and chronic (long-
1643 term) exposures while other possible scenarios commonly referred to such as "less than lifetime " were
1644 excluded from the comparisons, mainly because these methods were not consistently used or
1645 considered as not being sufficiently established in the regulatory areas examined. However, in certain
1646 cases, based on a specific toxicological profile of a substance, it may be appropriate to consider
1647 scenarios based on intermittent, fluctuating and peak exposures that are not consistent with chronic
1648 exposure and are also not sufficiently covered by the acute exposure estimates. In such cases, it may

⁴⁹ For example, in the studies with veterinary medicinal products, animals are treated at the intended maximum dose/duration and food is obtained at the earliest possible time of legally possible food production (e.g., after the expiration of the withdrawal periods), whereas in practice much longer withdrawal periods usually occur (ii) also the default assumption regarding the frequency of occurrence of residues is probably too conservative (it is based on the assumption that all animals are treated and all samples contain residues, which is not consistent with available sales/consumption data). However, in the absence of reliable monitoring data, this is currently the only valid assumption we can make regarding the frequency of occurrence of residues.

⁵⁰ The term "relative" refers to a comparison of "bioavailability/bioaccessibility" of residues of a substance in food matrix compared to the formulation of the substance used in the corresponding study to quantify the toxicological effect. The default assumption is that both parameters would be identical ("bioequivalent") which is in many cases an overly conservative assumption (note: this approach would normally not be applicable in case of sensitive local effects, e.g. in the GI tract)

1649 be appropriate to assess exposure separately using an LLT approach complementary to acute/chronic
1650 exposure and to include this information in the risk characterisation.

1651 - Use of probabilistic methodologies: Increasingly, probabilistic methods (e.g. Monte Carlo methods)
1652 are being used to generate and analyse exposure distributions. Probabilistic and deterministic
1653 approaches, as currently used for regulatory processes, do not necessarily produce different estimates
1654 of dietary exposure for a population if enough iterations are performed, but probabilistic methods can
1655 provide better information on the variability of dietary exposure estimates as they consider all
1656 available data, i.e. the full range of values and variability for each parameter. The possibility of using
1657 such techniques when data requirements are met should be further pursued and explored.

1658 A change in the exposure assessment methodology may have a direct impact on the outcome of the
1659 risk assessment and consequently on risk management, which is closely linked to the outcome of the
1660 risk characterisation (e.g. the setting of numerical MRLs or other risk management measures). The
1661 group discussed risk management issues only in passing, but it was recognised that the impact on risk
1662 management may be particularly relevant when exposure estimates in a regulatory area differ
1663 significantly from previous assumptions due to the introduction of new methodologies (e.g. moving
1664 from a broader to a more specific methodology) or when new approaches are introduced (e.g. acute
1665 exposure assessment). However, a more detailed assessment of the scientific and legal/administrative
1666 implications can only be made once the harmonised methodologies are sufficiently clearly defined and
1667 implemented in the respective areas. Further, it is recognised that with any agreed change in approach
1668 it will be necessary to introduce sufficiently long transitional phases in order to make the necessary
1669 adjustments.

1670 **9. References (scientific and/or legal)**

- 1671 1) Arcella, et al (2019), Harmonized methodology to assess chronic dietary exposure to residues
1672 from compounds used as pesticide and veterinary drug, Critical Reviews in Toxicology, 49:1, 1-10,
1673 DOI: 10.1080/10408444.2019.1578729
- 1674 2) Commission Regulation (EU) 2018/782 of 29 May 2018 establishing the methodological principles
1675 for the risk assessment and risk management recommendations referred to in Regulation (EC) No
1676 470/2009
- 1677 3) Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the
1678 implementation of Regulation (EC) No 1831/2003 of the European Parliament and of the Council
1679 as regards the preparation and the presentation of applications and the assessment and the
1680 authorisation of feed additives
- 1681 4) EFSA (2019), The raw primary commodity (RPC) model: strengthening EFSA's capacity to assess
1682 dietary exposure at different levels of the food chain, from raw primary commodities to foods as
1683 consumed. European Food Safety Authority (EFSA) supporting publication 2019:EN-1532
1684 <https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/sp.efsa.2019.EN-1532>
- 1685 5) EFSA FEEDAP Panel (2017), Guidance on the assessment of the safety of feed additives for the
1686 consumer, EFSA Journal 2017; 15(10): 10.2903/j.efsa.2017.5022
1687 (<https://www.efsa.europa.eu/en/efsajournal/pub/5022>)
- 1688 6) FAO (2016), Submission and evaluation of pesticide residues data for the estimation of maximum
1689 residue levels in food and feed, ISBN 978-92-5-109133-3,
1690 <https://www.fao.org/3/i5452e/i5452e.pdf>

- 1691 7) FAO/WHO (2011) expert meeting on dietary exposure assessment methodologies for residues of
1692 veterinary drugs: final report including report of stakeholder meeting., ISBN 978 92 4 156449 6,
1693 http://www.fao.org/fileadmin/user_upload/agns/pdf/jecfa/Dietary_Exposure_Assessment_Methodologies_for_Residues_of_Veterinary_Drugs.pdf
1694
- 1695 8) FAO/WHO (2013), International estimated short-term intake (IESTI),
1696 https://www.who.int/foodsafety/chem/guidance_for_IESTI_calculation.pdf
- 1697 9) FAO/WHO (2016), Guidance document for the establishment of Acute Reference Dose (ARfD) for
1698 veterinary drug residues in food. http://www.who.int/foodsafety/chem/jecfa/Guidance_ARfD.pdf
- 1699 10) FAO/WHO (2018), Summary Report of the JECFA/JMPR Working Group on Residue Definition,
1700 https://www.who.int/foodsafety/areas_work/chemical-risks/SR-JECFA-JMPR.pdf
- 1701 11) FAO/WHO (2021), Discussion paper on definition of edible offal and other animal tissues of
1702 relevance for the purpose of harmonization and elaboration of maximum residue limits,
1703 [https://www.fao.org/fao-who-codexalimentarius/sh-
1704 proxy/zh/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252F
1705 Meetings%252FCX-730-25%252FWDs%252Frv25_09e.pdf](https://www.fao.org/fao-who-codexalimentarius/sh-proxy/zh/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FMeetings%252FCX-730-25%252FWDs%252Frv25_09e.pdf)
- 1706 12) EMA (CVMP) 2022, Guideline on the determination of withdrawal periods for edible tissues,
1707 EMA/CVMP/SWP/735325/2012 Rev.2
- 1708 13) EMA (CVMP) 2022, Guideline on determination of withdrawal periods for milk,
1709 EMA/CVMP/SWP/735418/2012 Rev.1
- 1710 14) OECD (2007), Test No. 505: Residues in Livestock, OECD Guidelines for the Testing of Chemicals,
1711 Section 5, OECD Publishing, Paris, <https://doi.org/10.1787/9789264061903-en>
- 1712 15) OECD. 2010. Guidance for the derivation of an acute reference dose,
1713 [https://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono\(2010\)15
1714 &doclanguage=en](https://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2010)15&doclanguage=en)
- 1715 16) Regulation (EC) No 396/2005 of the European Parliament and of the Council of 23 February 2005
1716 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and
1717 amending Council Directive 91/414/EEC Text with EEA relevance
- 1718 17) Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying
1719 down Community procedures for the establishment of residue limits of pharmacologically active
1720 substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and
1721 amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation
1722 (EC) No 726/2004 of the European Parliament and of the Council
- 1723 18) Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009
1724 concerning the placing of plant protection products on the market and repealing Council Directives
1725 79/117/EEC and 91/414/EEC
- 1726 19) Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September
1727 2003 on additives for use in animal nutrition
- 1728 20) Solecki R, Davies L, Dellarco V, Dewhurst I, Raaij Mv, Tritscher A. 2005. Guidance on setting of
1729 acute reference dose (ARfD) for pesticides. Food Chem Toxicol. 43:1569–1593

- 1730 21) VICH GL46 (2011), Studies to evaluate the metabolism and residue kinetics of veterinary drugs in
 1731 food-producing animals: metabolism study to determine the quantity and identify the nature of
 1732 residues, EMA/CVMP/VICH/463072/2009
- 1733 22) VICH GL48 (2015), Studies to evaluate the metabolism and residue kinetics of veterinary drugs in
 1734 food-producing animals: Marker-residue-depletion studies to establish product withdrawal periods,
 1735 EMEA/CVMP/VICH/463199/2009
- 1736 23) VICH GL54 (2016), Studies to evaluate the safety of residues of veterinary drugs in human food:
 1737 general approach to establish an acute reference dose (ARfD), EMA/CVMP/VICH/699251/2010
- 1738 24) VICH GL56 (2018), Studies to evaluate the metabolism and residue kinetics of veterinary drugs in
 1739 food-producing species: study design recommendations for residue studies in honey for
 1740 establishing MRLs and withdrawal periods, EMA/CVMP/VICH/176637/2014
- 1741 25) VICH GL57 (2019) on studies to evaluate the metabolism and residue kinetics of veterinary drugs
 1742 in food-producing species: marker residue depletion studies to establish product withdrawal
 1743 periods in aquatic species, EMA/CVMP/VICH/517152/2013
- 1744 26) World Health Organization (WHO) (2009) Principles and methods for the risk assessment of
 1745 chemicals in food. EHC 240, Chapter 6 (updated 2020): Dietary Exposure Assessment of
 1746 Chemicals in Food ([https://www.who.int/docs/default-source/chemical-safety/ehc240-chapter6-
 1747 edited\(4-1\).pdf?sfvrsn=96810319_0](https://www.who.int/docs/default-source/chemical-safety/ehc240-chapter6-edited(4-1).pdf?sfvrsn=96810319_0))

1748 **10. Abbreviations**

1749 (The precise definitions of the terms below may vary in different sectoral legislation and guidelines and
 1750 the reader is advised to consult the relevant texts for further details.)

ADI	Acceptable Daily Intake
ARfD	Acute Reference Dose
AUC	area under the curve
BMDL	Benchmark Dose Level
CCPR	Codex Committee on Pesticide Residues
CCRVDF	Codex Committee on Residues of Veterinary Drugs in Foods
CIFOCoss	FAO/WHO Chronic Individual Food Consumption – summary statistics
CVMP	Committee for Medicinal Products for Veterinary Use
EC	European Commission
EFSA	European Food Safety Authority
ECHA	European Chemicals Agency
EHC 240	Environmental Health Criteria 240
EMA	European Medicines Agency
EU	European Union

FACE	Feed additives consumer exposure
FAO	Food and Agriculture Organization
FBS	Food balance sheet
FEEDAP	Panel on Additives and Products or Substances used in Animal Feed
FoodEx	Multipurpose food classification and description system developed by EFSA
GC	Gas chromatography
GEADE	Global Estimate of Acute Dietary Exposure
GECDE	Global Estimate of Chronic Dietary Exposure
GEMS	Global Environment Monitoring System
GL	Guideline
HBGV	Health Based Guidance Value
HPLC	high performance liquid chromatography
HR	Highest Residue
HRP	Highest Reliable Percentile
IEDI	International Estimated Daily Intake
IESTI	International Estimated Short-Term Intake
JECFA	Joint FAO/WHO Expert Committee on Food Additives
JMPR	Joint FAO/WHO Meeting on Pesticide Residues
LC	Liquid chromatography
LOD	Limit of Detection
LOQ	Limit of Quantification
LLOQ	Low Limit of Quantification
LSC	Liquid Scintillation Counting
LTL	Less than lifetime exposure
MR	Marker Residue
MR:TR	Ratio Marker Residue : Total Residue Ratio
MRL	Maximum Residue Limit/Level
MS	Mass spectrometry
NFCS	National Food Consumption Surveys
NOAEL	No Observed Adverse Effect Level

NOEC	No Observed Effect Concentration
OECD	Organisation for Economic Co-operation and Development
PoD	Point of Departure
PRIMo	Pesticide Residue Intake Model
RAC	Raw Agricultural Commodity
RoC	Residue of Health Concern
RPC	Raw Primary Commodity
RPCD	Raw Primary Commodity derivatives
SD	Standard deviation
SFB	Standard Food Basket
TMDI	Theoretical Maximum Daily Intake
TPoD	Critical time point for risk characterisation
TR	Total Residue
ULOQ	Upper Limit of Quantification
UTL	Upper 95 % tolerance level with 95 % confidence
VICH	Veterinary International Conference on Harmonization
VMP	Veterinary Medicinal Product
WHO	World Health Organisation

1751